Archived Medical News Stories

Archived Drug Trial News Stories - 2011

Date	Title	Comments	Rating
2011-12-31	Additional financing to fund Advaxis' cervical cancer trials	0	None
2011-12-30	FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer	0	None
2011-12-29	GOG targeted therapy phase 3 clinical trial delays progression of advanced ovarian cancer	0	None
2011-12-29	Bevacizumab delays disease progression in ovarian cancer	0	None
2011-12-29	Emergent commences Phase 2 combination trial of TRUw-016 with bendamustine in relapsed CLL	0	None
2011-12-28	Critical considerations for adenovirus-based HIV vaccine trials	0	None
2011-12-28	IL-1 gene inactivation may reduce severe clinical complications of atherosclerosis	0	3
2011-12-27	CEL-SCI to expand Multikine Phase III trial in head and neck cancer	0	None
2011-12-26	Initial results from 22nd Century's X-22 Phase II-B smoking cessation trial	0	None
2011-12-23	Correcting anemia can preserve kidney function in many transplant recipients	0	None
2011-12-23	Top-line results from Noven's LDMP Phase 3 clinical study on menopausal VMS	0	None
2011-12-23	Abbott commences Esprit drug eluting BVS trial in peripheral artery disease	0	None
2011-12-23	ViroPharma to acquire Meritage	0	None
2011-12-23	Enrollment complete in two Anacor's tavaborole Phase 3 trials on onychomycosis	0	None
2011-12-23	Science journal names UNC HIV prevention study as 2011 Breakthrough of the Year	0	None
2011-12-23	ThromboGenics submits ocriplasmin BLA with FDA to treat symptomatic VMA	0	3
2011-12-23	EpiCept receives FDA approval to commence AmiKet Phase III trial for CIPN	0	None
2011-12-22	Azithromycin shows promise against trachoma-related blindness	0	None
2011-12-22	AVEO initiates enrollment in tivozanib and mFOLFOX6 Phase 2 combination trial for CRC	0	None
2011-12-22	Researchers evaluate Clade C HIV envelope protein in Phase I trial	0	None
2011-12-21	Denali Concrete Management initiates enrollment in CF101 phase 3 study for Dry Eye Syndrome	0	None
2011-12-21	Chlorthalidone may reduce risk of death in patients with systolic hypertension	0	None
2011-12-21	Antihypertensive drug therapy associated with longer life expectancy	0	None
2011-12-21	University of Western Ontario receives FDA approval to begin SAV001 HIV trial	0	None
2011-12-21	Vacc-4x nasal vaccine can effectively treat HIV	0	None
2011-12-21	UCB initiates EXXELERATE study in rheumatoid arthritis	0	None
2011-12-21	Takeda enters agreement to acquire Intellikine	0	None
2011-12-20	DHEA hormone may help a woman's menopausal symptoms, sex life	0	None
2011-12-20	Top-line results from Genzyme's teriflunomide and Rebif Phase III comparison trial on RMS	0	None
2011-12-20	Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 study on MDD	0	None
2011-12-20	Impax commences IPX159 Phase IIb trial in Restless Legs Syndrome	0	None
2011-12-19	Atox Bio to advance AB103 Phase 2 study with $3.25M financing	0	None
2011-12-19	Phase I clinical study of Selexys SelG1 for sickle cell disease completed	0	None
2011-12-19	ALS TDI, Biogen Idec and UCB enter agreement to study anti-CD40L antibody for ALS	0	None
2011-12-19	Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia	0	None
2011-12-19	GSK initiates rhACE2 phase IIa study for Acute Lung Injury	0	None
2011-12-19	Zalicus commences Z944 Phase 1 clinical trial for treatment of acute and inflammatory pain	0	None
2011-12-19	Diseases of the Colon & Rectum publishes results from Pacira's EXPAREL Phase 3 trial	0	None
2011-12-17	Combination of bevacizumab and chemoradiation safe, effective for nasopharyngeal carcinoma	0	None
2011-12-17	Enrollment complete in ThromboGenics, BioInvent TB-402 Phase IIb trial on VTE	0	None
2011-12-17	Immediate ART appears preferable to deferring treatment among recently infected HIV patients	0	None
2011-12-15	Positive results from Hatchtech's DeOvo Phase 2b trial on head lice	0	None
2011-12-15	Cereblon protein now holds hope in fight against multiple myeloma	0	None
2011-12-15	Vaginal progesterone safe and effective in preventing preterm birth	0	None
2011-12-15	Vaginal progesterone reduces rate of preterm birth and neonatal complications	0	None
2011-12-15	AtheroNova establishes clear development plan for AHRO-001 after positive FDA feedback	0	None
2011-12-15	JHN to initiate new Phase I immunotherapy trial in glioblastoma	0	None
2011-12-15	Isis announces addition of three new drug development candidates	0	None
2011-12-15	Ganitumab shows promise in early-phase trials for metastatic pancreatic cancer	0	None
2011-12-14	Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL	0	None
2011-12-14	Positive data from Nektar's NKTR-181 Phase 1 clinical study for chronic pain	0	None
2011-12-14	Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM	0	None
2011-12-14	Maraviroc reduces incidence of GvHD in blood cancer patients after ASCT	0	None
2011-12-14	CTI, Chroma announce final results from tosedostat phase II study on AML	0	None
2011-12-14	JDRF initiates enrollment in metformin clinical study for type 1 diabetes	0	None
2011-12-14	Positive results from Aestus' ATx08-001 Phase II study on post-herpetic neuralgia	1	None
2011-12-14	ImmusanT secures $20M in Series A financing	0	None
2011-12-14	Vorinostat in addition to chemotherapy drugs improves remission rates in AML patients	0	None
2011-12-13	Incyte announces further analyses from Jakafi Phase III trial on myelofibrosis	0	None
2011-12-13	Ruxolinitib reduces spleen size by 35% in patients with myelofibrosis	0	None
2011-12-13	ISIS-FXIRx reduces Factor XI activity without bleeding in healthy volunteers	0	None
2011-12-13	S*BIO announces results from pacritinib Phase 2 study on myelofibrosis	0	None
2011-12-13	Combination of bortezomib and panobinostat shows promise against advanced MM	0	None
2011-12-13	Synta's ganetespib shows potent in vitro and in vivo activity against multiple breast cancer types	0	None
2011-12-13	Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS	0	None
2011-12-13	Plexxikon announces scientific findings from PLX3397 preclinical studies on AML	0	None
2011-12-13	Three-drug combination therapy appears to be effective for newly diagnosed MM patients	0	None
2011-12-13	Geron commences GRN1005 Phase 2 trial in breast cancer	0	None
2011-12-12	Soligenix reports results from orBec Phase 2 trial on acute GVHD	0	None
2011-12-12	Treatment with leukemia patients' own cells may prevent infections after chemotherapy	0	None
2011-12-12	Celgene announces interim results of REVLIMID study on CLL	0	None
2011-12-12	Research assesses safety and efficacy of pre-operative transfusions, hydroxyurea therapy for SCD	0	None
2011-12-12	Research examines novel treatment techniques for hemophilia B, VTE	0	None
2011-12-12	Onconova announces data from five rigosertib clinical trials on MDS	0	None
2011-12-12	Re-treatment with rituximab may benefit patients with LTB follicular lymphoma	0	3
2011-12-12	PCI-32765 is highly active and well tolerated in patients with CLL	0	None
2011-12-12	Onyx announces data from three carfilzomib studies on RRMM	0	None
2011-12-12	New findings from Micromet's blinatumomab phase 1 trial on DLBCL	0	None
2011-12-12	New research on diagnosis and treatment of leukemia to be presented at 53rd ASH meeting	0	None
2011-12-12	Syndax announces data from entinostat phase 2 study on HL	0	None
2011-12-12	SCRI to present findings of blood cancer trials at 53rd ASH annual meeting	0	None
2011-12-12	Positive dose-escalation/expansion data from Array BioPharma's ARRY-614 Phase 1 MDS study	0	None
2011-12-12	Obese women with early-stage HER2-positive breast cancer may have poorer outcomes	0	None
2011-12-12	Celgene announces results from azacitidine Phase 1 study on AML	0	None
2011-12-12	PCI-32765 produces durable remissions in Phase I/II CLL clinical trial	0	None
2011-12-12	New data from TetraLogic's TL32711 study on AML presented at 53rd ASH meeting	0	None
2011-12-12	ACE inhibitors, ARBs have different effects on heart health of dialysis patients	0	3
2011-12-12	Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV	0	None
2011-12-12	Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting	1	None
2011-12-09	Science examines HIV prevention trials, challenges to implementing new strategies	0	None
2011-12-09	Trastuzumab improves long-term outcomes in obese patients with HER2-positive breast cancer	0	None
2011-12-09	Shorter, effective treatment for latent TB infection	0	None
2011-12-09	Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium	0	None
2011-12-09	Enrollment complete in Boehringer Ingelheim's BI 201335 Phase III trial for HCV	0	None
2011-12-09	VIVUS announces results of Qnexa clinical study on cardiometabolic disease	0	None
2011-12-09	Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC	0	None
2011-12-09	Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout	0	None
2011-12-09	Galectin Therapeutics to initiate GM-CT-01 Phase 1/2 combination study in advanced MM	0	None
2011-12-09	ChemoCentryx commences CCX140 Phase II trial in diabetic nephropathy	0	None
2011-12-08	Combination of two anti-estrogen drugs extends survival time of women with breast cancer	0	None
2011-12-08	Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer	0	None
2011-12-08	Inviragen presents DENVax Phase 1 trial results on dengue at ASTMH annual meeting	0	None
2011-12-08	PrEP shows promise against HIV infection	0	None
2011-12-08	Notch inhibitor appears to treat breast cancer	0	None
2011-12-08	Influenza shot boosts immune response in pregnant women, protects neonatal babies	0	None
2011-12-08	Combination treatment extends lives of women with metastatic breast cancer	0	None
2011-12-08	Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC	0	None
2011-12-08	Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer	0	None
2011-12-08	Positive results from Pearl Therapeutics' PT001 Phase 2b trial on COPD	0	None
2011-12-07	ZIOPHARM receives European patent allowance for palifosfamide to treat cancer	0	None
2011-12-07	FDA modifies requirements of Amgen's Nplate REMS Program	0	None
2011-12-06	Positive final results from BioLineRx BL-1021 Phase Ia study for neuropathic pain	0	None
2011-12-06	PDUFA goal date of NDA for Protalix's taliglucerase alfa extended	0	None
2011-12-06	Study reveals mechanism of action of laquinimod in patients with RRMS	0	None
2011-12-06	VIVUS announces multiple abstracts on avanafil presented at ESSM meeting	0	None
2011-12-06	Top-line primary endpoint data from Pfizer's Toviaz trial on overactive bladder	0	None
2011-12-05	EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting	0	None
2011-12-05	Preliminary top-line results from XenoPort's XP21279 Phase 2 trial for advanced Parkinson’s disease	0	None
2011-12-05	Unigene acquires exclusive worldwide rights to oral PTH program from GSK	0	None
2011-12-05	NanoViricides submits pre-IND Meeting Request for FluCide to FDA	0	None
2011-12-05	Targacept commences two clinical studies of TC-5619 for schizophrenia and ADHD	0	5
2011-12-05	Zalicus commences Z160 Phase 1 clinical trial for pain	0	None
2011-12-05	Post-baseline vision data from Lundbeck's Sabril patient registry presented at AES meeting	0	None
2011-12-03	CDER, Shire enter agreement for ProAmatine clinical trial to treat symptomatic orthostatic hypotension	0	None
2011-12-03	Brazil's ANVISA grants registration for child-adapted formulation of benznidazole for Chagas disease	0	None
2011-12-03	Progesterone can benefit women with catamenial seizures: Study	0	None
2011-12-03	Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint	0	5
2011-12-03	Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV	0	None
2011-12-02	Bristol-Myers Squibb, Tibotec partner for TMC435 Phase II combination study in HCV	0	None
2011-12-02	John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting	0	None
2011-12-02	Scottsdale resident donates $1 million to TGen pancreatic cancer initiative	0	None
2011-12-02	Idera receives FDA notification to proceed with IMO-3100 Phase 2 clinical trial for psoriasis	0	None
2011-12-02	AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab	0	None
2011-12-01	ADVENTRX, FDA discuss ANX-188 development plans for treatment of sickle cell crisis	0	None
2011-12-01	Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus	0	None
2011-12-01	Enrollment complete in Ceregene's CERE-120 Phase 2b trial for Parkinson's	0	None
2011-12-01	Auxilium initiates XIAFLEX phase IIa trial in Frozen Shoulder syndrome	0	None
2011-12-01	Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma	0	None
2011-12-01	Statens Serum Institut, Aeras initiate new candidate TB vaccine Phase I trial	0	None
2011-12-01	Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer	0	None
2011-11-30	Combination treatment improves progression-free survival in pancreatic neuroendocrine tumors	0	None
2011-11-30	Neogenix novel antibody selected as one of Windhover's 2011 Top 10 Projects to Watch	0	None
2011-11-30	Genentech announces results from pertuzumab studies on HER2-positive breast cancer	0	None
2011-11-30	BioMarin commences GALNS Phase 2 study in mucopolysaccharidosis IVA	0	None
2011-11-29	Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection	0	None
2011-11-29	FDA assigns priority-review designation for ELIQUIS NDA for stroke prevention in atrial fibrillation	0	None
2011-11-29	Testing of vaginal gel for HIV prevention halted after interim results showed no difference from placebo	0	None
2011-11-29	Selcia completes 14C radiolabelled API projects for clients	0	None
2011-11-29	VOICE continues testing daily use of ARV Truvada among women in sub-Saharan Africa	0	None
2011-11-28	Tenofovir gel no more effective than placebo gel in preventing HIV	0	None
2011-11-28	FDA grants IND for AEZS-130 Phase 2A trial in cancer cachexia	0	None
2011-11-28	Inviragen commences DENVax Phase 2 trial for dengue	0	None
2011-11-28	Enrollment complete in SUSTAIN Phase 2b clinical trial for atherosclerotic CVD	0	None
2011-11-28	Inspiration commences enrollment in second OBI-1 Accur8 clinical trial program for congenital hemophilia A	0	None
2011-11-28	Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China	0	None
2011-11-28	Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia	0	None
2011-11-28	Exelixis and NCI's CTEP enter CRADA to further evaluate cabozantinib	0	None
2011-11-28	Inspiration initiates second OBI-1 phase III clinical trial in congenital hemophilia A with inhibitors	0	None
2011-11-25	Immunicum receives Swedish approval to commence first clinical trial of patented cancer vaccine	0	None
2011-11-23	Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC	0	None
2011-11-23	Treatment of Type 1 diabetes patients with DiaPep277- may have several medical benefits	0	None
2011-11-22	Arginine may reactivate T-cells in patients with glioblastoma	0	None
2011-11-22	Study: Vaccine development efforts currently focus on incidence rather than mortality rates	0	None
2011-11-21	Nature Medicine publishes dexpramipexole Phase 2 ALS study results	0	None
2011-11-21	Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy	0	None
2011-11-21	SAFC commences process validation activities for Oncolytics' REOLYSIN	0	None
2011-11-21	PLoS ONE publishes study on darinaparsin, a multivalent chemotherapeutic	0	4
2011-11-21	Consistent data from three studies support plans for rindopepimut with ACT IV Phase 3 study	0	None
2011-11-21	Multi-center cabozantinib trial for hormone receptor-positive breast cancer with bone metastases initiated	0	None
2011-11-21	Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis	0	None
2011-11-21	Selecta commences SEL-068 Phase 1 clinical trial for smoking cessation and relapse prevention	0	None
2011-11-21	ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris	0	None
2011-11-21	EMA validates Pfizer's Market Authorisation Application for tofacitinib to treat rheumatoid arthritis	0	None
2011-11-21	Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain	0	None
2011-11-20	Promising results from dexpramipexole phase 2 trial on ALS	0	None
2011-11-19	PEPFAR Scientific Advisory Board report offers six recommended research priorities	0	None
2011-11-19	Combo hormone therapy increases risk of breast cancer in women with new-onset tenderness	0	None
2011-11-18	Merrimack initiates MM-121 Phase 2 combination trial in metastatic NSCLC	0	None
2011-11-18	FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC	0	None
2011-11-18	FDA assigns new PDUFA date for Takeda's investigational type 2 diabetes therapy, alogliptin	0	None
2011-11-18	Tonix to initiate TNX-102 PK and BA study for fibromyalgia	0	None
2011-11-18	Inovio announces results from SynCon avian influenza vaccine Phase I study	0	None
2011-11-17	Biothera completes enrollment in Imprime PGG Phase II combination study on NSCLC	0	None
2011-11-17	Aurora kinase inhibitor may treat neuroendocrine prostate cancer	0	None
2011-11-17	Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial	0	None
2011-11-17	Mycophenolate mofetil superior to azathioprine for lupus nephritis	0	None
2011-11-17	New 2-DG-ABT combination cancer therapy triggers apoptosis	0	5
2011-11-17	Bionovo initiates Menerba Phase 3 trial in menopausal hot flashes	0	5
2011-11-16	Additional results from BioSante's LibiGel pK study on HSDD	0	None
2011-11-16	First clinical trial of dapivirine-maraviroc ring to treat HIV in women	0	None
2011-11-16	NIAID's ACTG and TB Alliance partner to complete moxifloxacin Phase III trial	0	None
2011-11-16	Rosuvastatin as effective as atorvastatin in reversing atherosclerosis	0	None
2011-11-16	Amgen's XGEVA delays onset of bone metastases in men with prostate cancer	0	None
2011-11-15	Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis	0	None
2011-11-15	Pneumococcal vaccine Prevnar13 effective in seniors	0	None
2011-11-15	Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome	0	None
2011-11-15	ProFibrix Fibrocaps effectively reduces bleeding in liver resection surgery	0	4
2011-11-15	POZEN reports positive Phase 1 study results comparing PA32540 to clopidogrel for CVDs	0	1
2011-11-15	Encouraging results from KAEL-GemVax GV1001 Phase II trial on NSCLC	0	3
2011-11-15	Mesoblast reports positive Revascor Phase 2 heart failure trial results	0	None
2011-11-14	Provectus presents data from PV-10 Phase 2 study at 2011 International Melanoma Congress	0	None
2011-11-14	Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial	0	None
2011-11-14	Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals	0	None
2011-11-14	Top-line results from Probiodrug's PQ912 Phase 1 SAD, MAD study for Alzheimer's disease	0	None
2011-11-14	A shot to lower 'bad' cholesterol	0	None
2011-11-14	Cerulean to present positive CRLX101 progression-free survival time results at 2011 AACR-NCI-EORTC	0	None
2011-11-14	Concert to initiate CTP-499 Phase 2 diabetic nephropathy clinical trial in 2012	0	None
2011-11-14	Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers	0	None
2011-11-14	Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints	0	None
2011-11-14	Amplification of ALK gene may drive rapid breast cancer metastasis	0	None
2011-11-14	Exelixis reports cabozantinib phase 2 trial data on bone metastases	0	None
2011-11-14	Feraheme as safe and effective as iron sucrose in patients with anemia, CKD	0	None
2011-11-14	New data on TetraLogic's TL32711 cancer drug to be presented at AACR-NCI-EORTC conference	0	None
2011-11-14	Patients with KRAS mutant NSCLC should respond well to antifolates	0	None
2011-11-14	Sitagliptin as safe and effective as glipizide in patients with type 2 diabetes, CKD	0	None
2011-11-11	Ampion safe and effective for patients with nasal inflammation	0	None
2011-11-11	NCCN ORP to evaluate clinical effectiveness of Boehringer Ingelheim's Afatinib in solid tumors	0	None
2011-11-11	Provectus announces data from Phase 2 PV-10 metastatic melanoma study	0	None
2011-11-10	Positive results from Alkermes VIVITROL addiction study	0	None
2011-11-10	Combination of azacitidine and entinostat shows promise against NSCLC	0	None
2011-11-10	Clinilabs to utilize NewCardio's QTinno in Phase I trial of new CNS drug	0	None
2011-11-09	Large-scale trials show HPV vaccine effective against multiple strains, could reduce need for screening	0	None
2011-11-09	Enrollment complete in Anacor's first of two tavaborole Phase 3 trials for onychomycosis	0	5
2011-11-09	Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis	0	None
2011-11-09	EI-IC bypass surgery does not lower risk of stroke recurrence in patients with TIA	0	None
2011-11-09	Infinity third quarter total revenue increases marginally to $23.3 million	0	None
2011-11-09	First-ever phase 1 clinical trial of rectal HIV-prevention drug	0	None
2011-11-09	Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint	0	None
2011-11-09	Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV	0	None
2011-11-09	Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients	0	None
2011-11-09	Positive results from ChemoCentryx CCX354 Phase II study on RA	0	None
2011-11-09	Micromet's blinatumomab data to be reported at 53rd ASH annual meeting	0	None
2011-11-08	Celldex Therapeutics initiates CDX-1127 Phase 1 study in malignant solid tumors	0	None
2011-11-08	Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis	0	None
2011-11-08	New results from BioCryst's BCX4208 Phase 2b gout study	0	None
2011-11-08	Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 studies on MDD	0	None
2011-11-08	MBL-HCV1 can reduce viral load in liver transplant patients	0	None
2011-11-08	First large-scale study to address treatment of prescription opioid addiction	0	None
2011-11-07	New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting	0	None
2011-11-07	Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting	0	None
2011-11-07	HyQ phase III study data in patients with primary immunodeficiencies presented at ACAAI meeting	0	None
2011-11-07	NewCardio's automated cardiac safety solution selected by top pharma company for Phase I drug study	0	None
2011-11-07	ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment	0	None
2011-11-07	KYTHERA presents long-term results from ATX-101 Phase 2 study at ASDS 2011	0	None
2011-11-07	Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism	0	None
2011-11-07	Abbott announces results from HUMIRA Phase 3 study on axSpA	0	None
2011-11-07	Encouraging results from SEEK's FLU-v Phase II study	0	None
2011-11-07	UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting	0	None
2011-11-07	Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011	0	None
2011-11-07	New data from Novartis' ACZ885 Phase III study on SJIA	0	None
2011-11-07	Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV	0	None
2011-11-07	New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA	0	None
2011-11-07	Rheumavax safe and feasible in treating RA	0	None
2011-11-07	New data from Savient's KRYSTEXXA Phase III trial on refractory chronic gout	0	None
2011-11-07	Vitamin D supplementation benefits people with lupus	0	None
2011-11-07	Children with polyarticular JIA benefit from early and aggressive therapy	0	None
2011-11-06	Final results from Vertex VX-509 Phase 2a study on RA	0	None
2011-11-06	New data from Santaris Pharma miravirsen Phase 2a trial on HCV	0	None
2011-11-06	Cystic fibrosis drug shows promise in trial	0	None
2011-11-05	Human Genome Sciences to present abstracts regarding BENLYSTA, SLE at ACR/ARHP meeting	0	None
2011-11-05	Sunovion reports positive results from ciclesonide nasal aerosol Phase III study for perennial allergic rhinitis	0	None
2011-11-05	Presidio Pharmaceuticals advances with its HCV antiviral drug discovery, development programs	0	5
2011-11-05	Results of Phase 2 program to develop NSAIDs to be reported at ACR annual meeting	0	None
2011-11-05	SCRIP honors Glenmark for business excellence and innovative R & D capabilities	0	None
2011-11-05	Daily intake of Souvenaid improves memory in people with mild AD	0	3.7
2011-11-05	Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder	0	None
2011-11-05	Positive data from RegeneRx RGN-259 Phase 2 trial on dry eye syndrome	0	None
2011-11-04	Inhibitex third quarter revenue increases to $1.3 million	0	None
2011-11-04	Jennerex commences enrollment in JX-594 Phase 2b trial for HCC	0	None
2011-11-04	Final results from Vertex KALYDECO second of two Phase 3 studies on CF	0	None
2011-11-03	Senesco commences dosing in SNS01-T Phase 1b/2a clinical study for multiple myeloma	0	None
2011-11-03	Positive results from Clinuvel's US Phase II study of photoprotective drug, afamelanotide	0	None
2011-11-03	Abbott to highlight latest research findings on HUMIRA at ACR annual meeting	0	None
2011-11-03	Galectin Therapeutics forms Liver Fibrosis Clinical Trials Advisory Board	0	None
2011-11-03	FEIBA drug safe and effective for patients with hemophilia A	0	None
2011-11-03	Ivacaftor drug improves lung function in people with cystic fibrosis	1	None
2011-11-03	Final results from Medivir's TMC435 phase IIb study on genotype-1 hepatitis C	0	None
2011-11-02	Isis commences ISIS-GCGRRx and ISIS-GCCRRx Phase 1 studies for type 2 diabetes	0	None
2011-11-02	PSTC, FNIH Biomarkers Consortium launch clinical study to improve detection of kidney injury	0	None
2011-11-02	Targeted antibiotic safe and effective for irritable bowel syndrome	0	None
2011-11-02	Vitamin D does not confer benefits against mortality in postmenopausal women	0	None
2011-11-02	Ocrelizumab drug holds promise for multiple sclerosis	1	5
2011-11-02	Takeda receives FDA approval for VELCADE sNDA to treat MM	0	None
2011-11-02	Positive results from DARA's DB959 Phase 1b study on type 2 diabetes	0	None
2011-11-01	Pharmasset initiates PSI-7977 Phase 3 program for HCV	2	None
2011-11-01	Studies on effectiveness of new HCV therapies presented at 76th ACG meeting	0	None
2011-11-01	NPS announces new data from GATTEX Phase 3 study on short bowel syndrome	0	None
2011-11-01	Teva reports data from QNASL studies on seasonal and perennial allergic rhinitis	0	None
2011-11-01	UCB to present new data on Cimzia at ACG annual scientific meeting	0	None
2011-10-31	Aspirin may reduce risk of bowel cancer by half: Study	0	None
2011-10-31	Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine	0	None
2011-10-31	Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cancers	0	None
2011-10-31	Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies	0	None
2011-10-31	Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors	0	None
2011-10-31	YM BioSciences announces results of nimotuzumab Phase II study on DIPG	0	None
2011-10-31	Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines	0	None
2011-10-31	HAL Allergy initiates PURETHAL Mites PHASE II study	0	None
2011-10-29	Ovarian cancer patients with many folate receptors benefit from new therapy	0	None
2011-10-29	Glitazone treatment does not cause side effects in patients with metastatic thyroid cancer	0	None
2011-10-29	Not too early to consider funding for, distribution of malaria vaccine	0	None
2011-10-29	Some experts question early release of RTS,S malaria vaccine trial data	0	None
2011-10-29	BZL and ATLAB Pharma partner to develop 177Lu-J591 for metastatic prostate cancer treatment	0	None
2011-10-28	Reasons for caution about experimental malaria vaccine	0	None
2011-10-28	Sulodexide drug fails to benefit diabetes patients with kidney disease	0	None
2011-10-28	Lenvatinib may achieve partial response in thyroid, endometrial, and renal cancers	0	None
2011-10-28	Diabetic patients with mild kidney disease may benefit from vitamin B6 derivative	0	None
2011-10-28	Regeneron announces positive results from sarilumab Phase 2b trial on RA	0	None
2011-10-27	Bayer's regorafenib Phase 3 trial on metastatic colorectal cancer meets primary endpoint	0	None
2011-10-27	Gardasil vaccine safe and effective against anal cancer	0	None
2011-10-24	Biogen’s Multiple Sclerosis pill succeeds at a late phase clinical trial	0	2
2011-10-24	external Trigeminal Nerve Stimulation pediatric clinical trial for ADHD receives NeuroSigma funding	0	None
2011-10-24	Sustained 'vigilance and money' necessary to fight malaria	0	None
2011-10-24	Tenofovir gel confirmed to be effective against herpes in lab experiment, study shows	0	None
2011-10-24	FDA approves intraspinal injections in spinal cord stem cell ALS trial	0	5
2011-10-24	Lundbeck's ONFI receives FDA approval for treating seizures associated with Lennox-Gastaut syndrome	0	None
2011-10-24	European CHMP adopts positive opinion for Pharmaxis Bronchitol Marketing Authorisation	0	None
2011-10-24	Zeaxanthin reduces risk for AMD	0	None
2011-10-24	Vertex initiates INCIVEK combination Phase 3b study for hepatitis C	0	None
2011-10-24	Synergy commences plecanatide Phase II/III trial in chronic idiopathic constipation	0	None
2011-10-24	Top-line results from Exelixis' cabozantinib phase 3 trial on medullary thyroid cancer	0	None
2011-10-24	Mesoblast cleared to begin first phase 2 clinical trial for wet AMD	0	None
2011-10-24	Mirna, Silence enter agreement to assess delivery systems for novel microRNAs	0	None
2011-10-22	Pivotal pediatric clinical study comparing Q/LAIV to FluMist meets primary endpoint	0	None
2011-10-22	Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b trial for RRMS	0	None
2011-10-22	Sanofi announces new results from alemtuzumab-Rebif comparative CARE-MS I trial	0	None
2011-10-22	Ferring reports on FDA approval of labeling supplement for EUFLEXXA to treat knee osteoarthritis	0	None
2011-10-22	Pfizer's Prevnar 13: Additional data from adult clinical studies presented at 49th IDSA	0	None
2011-10-22	Janssen announces FDA label update approval for PREZISTA HIV tablets	0	None
2011-10-22	Additional data from Sanofi's quadrivalent inactivated influenza vaccine study	0	None
2011-10-22	Merz presents XEOMIN clinical data on dystonia at IDS 2011	0	5
2011-10-22	Positive top line results from Shire's LDX phase III study on ADHD	0	None
2011-10-22	NIH stops triple-drug therapy clinical trial for idiopathic pulmonary fibrosis	0	None
2011-10-22	Much work remains to be done in fight against malaria	0	None
2011-10-22	Romark announces results from NT-300 Phase 2B-3 trial on influenza	0	None
2011-10-22	Xencor commences XmAb5871 Phase 1 trial in autoimmune diseases	0	None
2011-10-22	Boehringer Ingelheim announces new data from hepatitis C virus portfolio	0	None
2011-10-21	Geron announces data from ongoing GRNOPC1 Phase 1 trial on spinal cord injury	0	None
2011-10-21	Genentech announces 96-week results from ocrelizumab Phase II study on RRMS	0	None
2011-10-21	OncoGenex commences enrollment in OGX-427 Phase II trial for bladder cancer	0	None
2011-10-20	Starting HIV therapy within two weeks of TB treatment increases survival by 33%	0	None
2011-10-20	TGen collaborates with Samuel Oschin Comprehensive Cancer Institute for clinical trials	0	None
2011-10-20	Rituximab may alleviate chronic fatigue syndrome through B-lymphocyte depletion	0	5
2011-10-20	EMA, FDA endorse use of biomarkers in Alzheimer's drug trials	0	None
2011-10-20	Despite progress in malaria vaccine development, funding remains potential stumbling block	0	None
2011-10-20	Experimental vaccine halves risk of malaria in African children, results of large clinical trial suggest	0	None
2011-10-19	Data from Concert Pharmaceuticals' CTP-499 study to be presented at ASN Kidney Week 2011	0	None
2011-10-19	Oral laquinimod shows promise against multiple sclerosis	0	5
2011-10-19	Topical corticosteroids show promise against bacterial corneal ulcers	0	None
2011-10-19	RTS,S vaccine reduces risk of severe malaria in African children	0	None
2011-10-18	First results from phase 3 malaria vaccine candidate trial	0	None
2011-10-18	FDA approves Oxford BioMedica's UshStat IND to treat Usher syndrome type 1B	0	5
2011-10-18	Takeda commences TAK-875 Phase 3 clinical trial program for type 2 diabetes	0	None
2011-10-18	Natroba effective against head lice and nits	0	None
2011-10-18	Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast cancer	0	None
2011-10-18	Dendreon initiates enrollment in DN24-02 Phase 2 trial for HER2 positive cancer	0	None
2011-10-18	ChemoCentryx commences CCX168 Phase II trial in ANCA-associated vasculitis	0	None
2011-10-15	ABI provides clinical update on company activities	0	None
2011-10-15	Janssen, BeiGene enter in-licensing agreement for two clinical-stage oncology compounds	0	None
2011-10-14	Four companies receive NIAID contracts to develop broad-spectrum therapeutics	0	None
2011-10-14	NIH-funded study to evaluate rescue medications for victims of toxic gases	0	None
2011-10-14	USAID award supports study of SILCS diaphragm plus tenofovir gel on HIV, HSV	0	None
2011-10-14	New dual drug combinations in development for various cancers	0	None
2011-10-14	Merck announces results from ISENTRESS Phase III combination study on HIV-1	0	None
2011-10-14	Micromet receives FDA feedback on blinatumomab registration for R/R ALL	0	None
2011-10-14	Positive data from Anadys' setrobuvir Phase IIb combination study on genotype 1 HCV	0	None
2011-10-14	JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM	0	None
2011-10-14	Baxter commences BAX 111 Phase III trial in von Willebrand disease	0	None
2011-10-14	InnaVirVax announces Phase I/IIa clinical trial authorization for its VAC-3S HIV vaccine	0	None
2011-10-13	Top-line results from POZEN's PA32540 Phase 3 trial on aspirin-associated gastric ulcers	0	None
2011-10-13	Hydromorphone can be as effective as diacetylmorphine in treating heroin addiction	0	None
2011-10-13	EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL	0	None
2011-10-12	Intellikine commences INK1117 Phase I dose escalation study in cancer	0	None
2011-10-12	Vitamin E supplements linked with increased risk of prostate cancer	0	None
2011-10-12	Daily vitamin E supplementation may increase risk of prostate cancer	0	None
2011-10-12	FDA grants Advaxis pre-IND meeting for ADXS-HER2 cancer immunotherapy	0	None
2011-10-12	AFFiRiS receives MJFF grant for clinical study of AFFITOPE PD01	0	None
2011-10-12	Shield commences two ST10 Phase 3 studies in iron deficiency anaemia	0	None
2011-10-12	NIH awards United Therapeutics $45 million contract to develop potential oral treatment for viruses	0	None
2011-10-12	Isis designates ISIS-AATRx candidate in collaboration with GSK	0	None
2011-10-12	Merrimack begins MM-121 Phase 2 combination trial in HER2-negative breast cancer	0	None
2011-10-12	Furiex announces publications and presentations about antibacterial drug JNJ-Q2	0	None
2011-10-12	UCSF, Anacor to discover and optimize novel oxaboroles as antimalarial drugs	0	None
2011-10-12	COPAXONE reduces loss of brain volume in patients with RRMS	0	None
2011-10-12	Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes	0	None
2011-10-11	DMC completes review of BioSante's LibiGel Phase III cardiovascular and breast cancer study	0	None
2011-10-11	Omeros initiates OMS302 Phase 3 trial in intra-ocular lens replacement surgery	0	None
2011-10-11	DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer	0	None
2011-10-11	Aduro initiates CRS-207 and GVAX Pancreas Cancer Vaccine Phase 2 clinical trial	0	None
2011-10-11	ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM	0	4
2011-10-11	Roche's gantenerumab removes amyloid plaques from the brain of patients with AD	0	None
2011-10-11	Takeda, Affymax announce data from multiple studies of peginesatide on anemia	0	None
2011-10-11	Positive results from Biotron's BIT225 Phase 2a trial on HCV	0	None
2011-10-10	Coridon demonstrates 100% protection using DNA HSV-2 vaccine	4	5
2011-10-10	Targacept commences AZD3480 Phase 2b study in Alzheimer’s disease	0	None
2011-10-10	Unither Virology receives NIAID contract for glycobiology antiviral platform	0	None
2011-10-10	Pharmasset adds two treatment arms to PSI-7977 ELECTRON trial on HCV	0	None
2011-10-07	Teriflunomide drug reduces relapse rate of people with MS	0	None
2011-10-07	JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer	0	None
2011-10-04	Karo Bio initiates patient recruitment in eprotirome phase III trial for HeFH	0	4
2011-10-04	Clinical study: Higher radiation dose does not improve overall survival for NSCLC	0	None
2011-10-04	DNA primer vaccine enhances immune response to H5N1 avian influenza vaccine	0	None
2011-10-04	Orexigen presents data from Contrave trial at 29th Annual Scientific Meeting of The Obesity Society	0	None
2011-10-04	Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV	0	None
2011-10-04	AMRI announces final results from ALB-127158(a) Phase I clinical studies on obesity	0	None
2011-10-03	Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy	0	None
2011-10-03	EntreMed announces data from ENMD-2076 Phase 2 study in platinum-resistant ovarian cancer	0	None
2011-10-03	Dosing commences in Auxilium's XIAFLEX phase IIIb trial for Dupuytren's contracture	0	None
2011-10-03	GeoVax completes enrollment for HIV/AIDS vaccine Phase 2a clinical trial	0	None
2011-10-03	Alkermes initiates ALKS 37 phase 2b study in opioid-induced constipation	0	None
2011-10-01	The Polyclinic participates in major international HDL clinical research study	0	None
2011-10-01	Planned clinical trial of Adeona's zinc-based therapy for ALS patients to be featured at ALS Summit	0	None
2011-10-01	Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011	0	None
2011-10-01	Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA	0	None
2011-10-01	New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011	0	None
2011-10-01	Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting	0	None
2011-10-01	Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer	0	None
2011-10-01	Baxter seeks European marketing authorization for HyQ to treat PI	0	None
2011-09-30	Roche inaugurates new clinical supply manufacturing facility in Nutley, N.J.	0	None
2011-09-30	Cincinnati Children's to conduct first medication clinical trial for pediatric migraine	0	None
2011-09-30	Array announces results from selumetinib Phase 2 combination study on KRAS-mutant NSCLC	0	5
2011-09-30	Small Phase I trial shows HIV vaccine candidate is most powerful to date	0	None
2011-09-30	Microbicide Trials Network stops tenofovir arm of study after findings show drug less effective than anticipated	0	None
2011-09-29	Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors	0	None
2011-09-29	Positive new data from Otonomy's OTO-104 Phase 1b study on Meniere's disease	0	None
2011-09-29	Cubist plans to move CB-183,315 into Phase 3 trial for treatment of CDAD	0	None
2011-09-29	DSMB authorizes ACT to proceed with next set of patients in stem cell clinical trials	0	5
2011-09-29	Cincinnati Children's to conduct first pediatric migraine medicine clinical trial	0	None
2011-09-29	Almirall submits linaclotide MAA to EMA for treatment of IBS-C	0	None
2011-09-29	VOICE HIV prevention trial to discontinue use of tenofovir tablets	0	None
2011-09-29	Enrollment complete in Rexahn's Archexin Phase II trial for metastatic pancreatic cancer	0	None
2011-09-29	SanBio initiates SB623 Phase 1/2a clinical trial in ischemic stroke	0	4
2011-09-28	Halozyme commences HTI-501 clinical trial for cellulite in women	0	None
2011-09-28	Phase I clinical trials reveal MVA-B preventive vaccine's immune efficiency against HIV	0	None
2011-09-28	Adamas begins ADS-5102 Phase 2/3 clinical trial in Parkinson's disease	0	None
2011-09-28	YM BioSciences begins enrollment in CYT387 Phase II trial for myelofibrosis	0	None
2011-09-28	Lovastatin appears to be safe, effective for children with neurofibromatosis type 1	0	None
2011-09-28	BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR	0	2.7
2011-09-28	MicroDose initiates MDT-637 Phase 1 trial in respiratory syncytial virus	0	None
2011-09-27	22nd Century completes enrollment in X-22 Phase II-B smoking cessation study	0	None
2011-09-27	The Nation examines rise in unregulated drug trials in South America	0	None
2011-09-27	HCRI completes enrollment in dual antiplatelet therapy clinical trial	0	None
2011-09-27	Afraxis to participate in NIH's Therapeutics for Rare and Neglected Disease Program	0	None
2011-09-27	Arena, Eisai announce new data from lorcaserin Phase 3 clinical trial program	0	None
2011-09-27	Elevation presents positive data from EP-101 Phase 2a study on COPD at ERS annual meeting	0	None
2011-09-27	Novartis files marketing authorisation with EMA for NVA237 to treat COPD	0	None
2011-09-27	Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011	0	None
2011-09-27	Zoledronic acid may extend survival in older breast cancer patients	0	None
2011-09-27	Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors	0	None
2011-09-27	Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia	0	None
2011-09-27	Collegium completes Type A meeting with FDA for COL-003 Phase III chronic low back pain study	0	None
2011-09-26	Smaller and faster clinical drug trials could improve gains in cancer survival	0	None
2011-09-26	Pacira announces data from EXPAREL clinical study presented at ASPS 2011 meeting	0	None
2011-09-26	Zoledronic acid may benefit post-menopausal women with breast cancer	0	None
2011-09-26	Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL	1	None
2011-09-26	Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer	0	None
2011-09-26	JDRF, iCo Therapeutics collaborate for iCo-007 Phase 2 trial in DME	0	None
2011-09-26	Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma	0	None
2011-09-26	Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL	0	None
2011-09-26	Ibandronate controls pain in prostate cancer patients with bone metastases	0	None
2011-09-26	InterMune reports new data from Esbriet clinical trial on IPF	0	None
2011-09-26	Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC	0	None
2011-09-26	Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint	0	None
2011-09-26	Combination of Afinitor, exemestane reduces risk of breast cancer progression in women	0	None
2011-09-26	Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials	0	None
2011-09-26	Combination of abiraterone acetate, prednisone reduces fatigue in men with prostate cancer	0	None
2011-09-26	Breast cancer drug combination could stop cancer “in its tracks”	0	None
2011-09-26	Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer	0	None
2011-09-26	Combination of chemo and radiotherapy in breast cancer: Trial	0	None
2011-09-26	Drug combo for breast cancer in post-menopausal women shows promise	0	None
2011-09-26	Zometa bone drug trial in post-menopausal women with breast cancer	0	None
2011-09-26	Embryonic stem cell therapy for incurable Stargardt eye disease	1	4
2011-09-26	The Journal of Pain publishes results from Butrans Transdermal System Phase 3 clinical study	0	None
2011-09-26	First Radium-223 Chloride Phase III study in prostate cancer	0	None
2011-09-26	Combination of everolimus, exemestane holds promise against post-menopausal breast cancer	0	None
2011-09-26	RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome	0	None
2011-09-26	Letrozole reduces risk of breast cancer recurrences and death in post-menopausal women	0	None
2011-09-23	EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection	0	None
2011-09-23	YM BioSciences total revenue decreases to $1.5 million for fiscal 2011	0	None
2011-09-23	Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011	0	None
2011-09-23	Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV	0	None
2011-09-23	E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug	0	None
2011-09-23	Soy protein reduces progression of atherosclerosis in women within 5 years of menopause	0	None
2011-09-23	Researchers to expand malaria vaccine study after initial trial yields encouraging results	0	None
2011-09-23	Researchers compare safety and effectiveness of cryotherapy, salicylic acid for verrucae	0	None
2011-09-23	Levosimendan may effectively improve muscle function in patients with respiratory failure	0	None
2011-09-23	Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011	0	None
2011-09-22	Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma	0	None
2011-09-22	Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC	0	None
2011-09-22	Aradigm announces two ciprofloxacin Phase 2b study data on non-CF bronchiectasis	0	None
2011-09-22	Theraclone initiates TCN-032 Phase 1 trial in influenza A	0	None
2011-09-22	NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF	0	None
2011-09-22	S-equol improve appearance of crow's feet skin wrinkles in Japanese menopausal women	0	None
2011-09-21	HRPR before PCI procedures linked to increased risk of ischemic event in ACS patients	0	None
2011-09-21	Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD	0	None
2011-09-21	Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA	0	None
2011-09-21	Positive results from Orexo's OX219 clinical study on opioid dependence	0	None
2011-09-20	Niiki Pharma announces positive data from ongoing trial of novel anti-cancer agent NKP-1339	0	None
2011-09-20	Gilead’s new 4 in 1 combo HIV pill works	0	None
2011-09-20	U-M Professor to review data from three prominent studies on heart failure	0	None
2011-09-20	Gilead’s Quad Phase 3 clinical study in treatment-naïve HIV-1 patients meets 48-week primary objective	0	None
2011-09-20	New research has potential to alleviate side effects of cancer treatments	0	None
2011-09-20	Tokai raises $23M in Series D3 financing	0	None
2011-09-20	Major donors should consider funding for potential malaria vaccine	0	None
2011-09-20	Top-line data from Santarus' budesonide MMX extended use study on ulcerative colitis	0	None
2011-09-20	Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia	0	5
2011-09-20	Infant formulas fortified with LCPUFA are good for developing brains and hearts	0	None
2011-09-20	LA BioMed andrologist leads new male contraceptive Phase I clinical study	0	None
2011-09-20	Scientists pioneer new combination treatment for prostate cancer	0	None
2011-09-20	Positive data from NovaDigm's NDV-3 vaccine preclinical study on VVC	0	None
2011-09-19	Preclinical studies shows EmPAC more effective than Taxol	0	None
2011-09-19	Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD	0	None
2011-09-19	Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC	0	None
2011-09-19	Tarsa reports positive data from OSTORA Phase III ORACAL trial for postmenopausal osteoporosis	1	5
2011-09-19	Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma	0	None
2011-09-19	Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients	0	None
2011-09-19	Aestus to develop ATx09-002 for treatment of neuropathic pain	0	None
2011-09-19	Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia	0	None
2011-09-19	Karo Bio receives approval to initiate eprotirome phase III study in HeFH	0	None
2011-09-19	NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting	0	None
2011-09-19	Positive data from Tarsa's OSTORA Phase III trial on postmenopausal osteoporosis	0	None
2011-09-17	Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis	0	None
2011-09-17	Additional data on safety, tolerability of Cempra's solithromycin to be presented at 51st ICAAC	0	None
2011-09-17	Multiple abstracts on QNEXA presented at 47th EASD	0	None
2011-09-17	DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain	0	None
2011-09-17	BARDA awards Vaxin $21.7M contract to accelerate development of novel anthrax vaccine	0	None
2011-09-16	ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes	0	None
2011-09-16	Linagliptin demonstrates durable reductions in blood glucose for T2D adults	0	None
2011-09-16	Combination of prasugrel plus ASA can treat acute coronary syndrome	0	None
2011-09-16	Anavex announces ANAVEX pre-clinical data on Alzheimer's disease	0	None
2011-09-16	Potential new treatment for fragile X syndrome	0	None
2011-09-16	Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients	0	5
2011-09-16	Experimental malaria vaccine shows positive results among children in small Burkina Faso study	0	None
2011-09-16	Probiotics appear to protect against upper respiratory tract infections	0	None
2011-09-16	Azithromycin gel may treat borreliosis in humans	0	None
2011-09-16	Diclofenac in nano-formulated doses provides effective pain relief	0	None
2011-09-15	CRF announces late breaking trials & first report investigations to be presented at TCT 2011	0	None
2011-09-15	Anavex Life Sciences to present data on lead compound for Alzheimer’s at Japan Neuroscience Society	0	None
2011-09-15	International patient groups anxiously await start of Huntington’s trial	0	5
2011-09-15	KAI enters KAI-4169 development and commercialization agreement with Ono	0	None
2011-09-15	Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment	0	None
2011-09-15	NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma	0	None
2011-09-15	Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes	0	5
2011-09-15	Patients with hepatitis C may benefit from 24 week telaprevir-based regimen	0	None
2011-09-15	Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis	0	None
2011-09-15	First effective blood-stage vaccine against malaria	0	5
2011-09-15	NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C	0	None
2011-09-15	SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease	0	None
2011-09-15	Scientist granted over $138,000 to explore Vitamin C therapy in sepsis	0	5
2011-09-15	Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes	0	None
2011-09-14	Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections	0	None
2011-09-14	Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer	0	None
2011-09-14	Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study	0	None
2011-09-14	New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011	0	None
2011-09-14	Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma	0	None
2011-09-14	Lexicon's LX4211 clinical data presented at EASD annual meeting	0	None
2011-09-14	VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting	0	None
2011-09-14	ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE	0	None
2011-09-14	Acceleron commences ACE-536 Phase 1 clinical trial in anemia	0	None
2011-09-13	New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress	0	None
2011-09-13	Researchers use MRI and PET/CT to assess safety, efficacy of heart drug dalcetrapib	0	None
2011-09-13	Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference	0	None
2011-09-13	ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM	0	None
2011-09-12	Clinical trial planned in Australia and the USA to help patients with ‘orphan’ disease	0	4.3
2011-09-12	Sanofi's Lyxumia achieves primary efficacy endpoint in study of patients uncontrolled on metformin	0	None
2011-09-12	Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer	0	None
2011-09-12	BioSante reports top-line results from LibiGel PK study for HSDD in postmenopausal women	0	None
2011-09-12	Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease	0	None
2011-09-12	Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC	0	3
2011-09-12	InteRNA, Silence partner to develop novel microRNA therapeutics for cancer	0	None
2011-09-12	Recruitment complete in Moberg Derma's MOB-015 phase II study for nail fungus	1	None
2011-09-12	Roche initiates Phase 1 clinical trial of investigational drug for Down syndrome	0	5
2011-09-12	UMSOM to receive FDA approval for whole parasite malaria vaccine clinical trials	0	None
2011-09-12	Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer	0	None
2011-09-09	Sangamo's SB-728-T Phase 1 study data on HIV/AIDS to be presented at ICAAC conference	0	4
2011-09-09	Fewer doses of Cervarix vaccine may be as efficacious as standard three-dose regimen	0	None
2011-09-09	Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban	0	None
2011-09-09	Sagene completes SPI-1972 pre-IND meeting with FDA for erectile dysfunction	0	None
2011-09-09	Positive results from Sanaria PfSPZ Vaccine initial Phase 1 trial on malaria	0	None
2011-09-08	OptiNose chooses BioClinica's advanced imaging and IWR solutions for clinical trials	0	None
2011-09-08	Lilly, Boehringer Ingelheim to present latest data from diabetes portfolio at 47th EASD meeting	0	None
2011-09-08	Better communication needed with at-risk communities for HIV vaccine trials	0	None
2011-09-08	Adding azithromycin to usual daily treatment for COPD reduces acute exacerbations by 27%	0	None
2011-09-07	Top-line results from Teva-Alcobra MG01CI Phase II trial for ADHD	0	None
2011-09-07	Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA	0	None
2011-09-07	Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects	0	None
2011-09-07	Cancer Research UK opens olaparib-temozolomide combination Phase I trial in glioblastoma	0	None
2011-09-07	ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme	0	None
2011-09-07	GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052	0	None
2011-09-07	Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data	0	None
2011-09-06	Positive results from BDSI's BEMA Buprenorphine/Naloxone formulation Phase 1 study on opioid dependence	0	None
2011-09-06	Enrollment complete in DURECT's POSIDUR Phase III study for post-surgical pain	0	None
2011-09-06	Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints	0	None
2011-09-06	Shiva Biomedical, CorMedix to extend CRMD001 phase III trial in chronic kidney disease	0	None
2011-09-06	ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL	0	None
2011-09-06	Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1	0	None
2011-09-06	NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease	0	None
2011-09-06	Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma	0	None
2011-09-06	Chondroitin sulfate decreases pain and improves hand function in patients with OA	0	None
2011-09-06	BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer	0	None
2011-09-05	Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks	0	None
2011-09-05	Gilead to amend design of ongoing clinical trials against chronic hepatitis C	0	None
2011-09-03	SWOG selects four cancer researchers for 2011 Young Investigator Training Course	0	None
2011-09-02	Dr. Reddy’s initiates DRL-17822 Phase II study in type II dyslipidemia	0	None
2011-09-02	New meta-analysis reaffirms safety profile of aspirin for pain relief, fever	0	None
2011-09-02	Valproic acid may increase survival for brain tumor patients	0	None
2011-09-02	New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress	1	None
2011-09-02	UTHealth to study BMS-820836 in Phase II trial for major depressive disorder	0	None
2011-08-31	Medivir completes enrollment of three TMC435 phase 3 trials on CHC genotype-1 infection	0	None
2011-08-31	Eisai announces results of perampanel Phase III study on epilepsy	0	None
2011-08-31	Positive results from Bionovo's Menerba tolerability trial on menopausal hot flashes	0	None
2011-08-31	Enrollment commences in Adamis' APC-100 Phase 1/2a clinical prostate study	0	None
2011-08-31	Positive results from Pearl's formoterol fumarate MDI Phase 2b trial on moderate-to-severe COPD	0	None
2011-08-31	Favorable top-line results from Aeterna Zentaris' AEZS-130 Phase 3 study on AGHD	0	None
2011-08-30	Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting	0	None
2011-08-30	Bristol-Myers Squibb selects ICON as preferred provider for early phase clinical development	0	None
2011-08-30	ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma	0	None
2011-08-30	Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress	0	None
2011-08-30	Bristol Meyer Squibb’s new blood thinner drug for stroke prevention	0	None
2011-08-29	Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer	0	None
2011-08-29	Dabigatran etexilate superior to warfarin for stroke prevention in AF patients	0	2
2011-08-29	Everolimus-eluting stent and SES are equally effective for PCI patients	0	None
2011-08-29	Statins protect people against death from respiratory illness, infections	0	None
2011-08-29	ELIQUIS better than warfarin in reduction of stroke, major bleeding, and mortality	0	None
2011-08-29	Colchicine more effective than placebo for recurrent pericarditis	0	None
2011-08-29	Apixaban superior to warfarin in preventing stroke and systemic embolism	0	None
2011-08-29	Azithromycin can help reduce wheezing, other acute symptoms of COPD	0	None
2011-08-26	BIPI to launch dabigatran etexilate Phase II trial in patients with mechanical heart valves	0	None
2011-08-26	Fludrocortisone may help reduce unexplained chronic nausea in children	0	5
2011-08-26	Nasal spray with hot chili pepper ingredient may help people clear up sinus inflammation	0	None
2011-08-26	Emergent announces results of adjuvanted BioThrax anthrax vaccine Phase 1a trial	0	None
2011-08-25	Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder	0	5
2011-08-25	PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine	0	None
2011-08-25	Azithromycin can effectively reduce acute COPD exacerbations	0	None
2011-08-24	Psoriasis drug and heart attack risk association unclear: Study	0	None
2011-08-24	KFDA approves IND for DP-b99 Phase III MACSI stroke study in Korea	0	None
2011-08-24	Kibow renews exclusive worldwide veterinary licensing and marketing agreement	1	None
2011-08-24	United Therapeutics completes treprostinil diethanolamine Phase 3 trial in PAH	0	None
2011-08-24	Avastin increases tumor response rates in breast cancer patients before surgery	0	None
2011-08-24	Celldex announces key in vivo efficacy results of CDX-1135 in Dense Deposit Disease	0	5
2011-08-24	Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma	0	4
2011-08-23	Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia	0	None
2011-08-23	Pearl selects TransPerfect's Trial Interactive eTMF solution for clinical development programs	0	3
2011-08-23	Spinifex secures AU$6.25 million in expanded Series B funding	0	None
2011-08-23	Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer	0	1
2011-08-22	Living Cell Technologies xenoimplants first patients in Argentina trial	0	None
2011-08-20	Researchers turn their attention to Chagas disease as developed countries see rise in infection rates	0	None
2011-08-19	VOA News examines ethics of clinical drug testing in African nations	0	None
2011-08-19	Time-release corticosteroid implant effective in treating uveitis	0	None
2011-08-19	Amgen to present data from several Prolia studies at ASBMR 2011 meeting	0	None
2011-08-19	NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy	0	None
2011-08-19	Minocycline, EDTA may combat catheter-related bacterial infections in dialysis patients	0	3
2011-08-19	FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug	0	None
2011-08-19	Antigen Express provides update on ongoing AE37 Phase 2 trial in breast cancer	0	None
2011-08-18	BTI completes SUGARDOWN human clinical study on blood sugar management	0	None
2011-08-18	New leukemia drug in early clinical testing offers some clues for better treatment	0	None
2011-08-18	FDA approves Mayo Clinic's ovarian and breast cancer vaccines	0	None
2011-08-18	NCRM at Case Western Reserve to host stem cell conference in Cleveland	0	None
2011-08-18	Clinical trials to evaluate and validate infrastructure of P-medicine consortium	0	None
2011-08-18	Endo terminates collaboration and axomadol development program with Grunenthal	0	None
2011-08-18	CEL-SCI receives Chinese patent for Multikine cancer drug	0	None
2011-08-18	Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma	0	None
2011-08-17	Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL	0	4
2011-08-17	Clinical trial to assess 6MP drug in women with advanced breast or ovarian cancer	0	None
2011-08-17	GeoVax receives NIH-NIAID grant for HIV/AIDS vaccine program	0	None
2011-08-17	Clinical Trials Partnership Middle East Summit to take place in Dubai	0	None
2011-08-17	Pegloticase can improve clinical outcomes of patients with chronic gout	0	None
2011-08-17	Patient recruitment complete in Kuros' KUR-023 dural sealant European clinical trial	0	None
2011-08-17	FDA clears Inhibikase IkT-001 Phase II trial to treat JCV infection in multiple sclerosis patients	0	None
2011-08-17	Curis initiates CUDC-101 Phase I combination trial in advanced head and neck cancer	0	None
2011-08-16	Patrys product shows activity in multiple myeloma cancer cells	0	None
2011-08-16	LYSOGENE launches the first gene therapy clinical trials in Sanfilippo disease	0	5
2011-08-16	Zinc lozenges might reduce duration of common cold episodes by 40%	0	None
2011-08-16	Pfizer, QIAGEN partner to develop diagnostic-therapeutic combination for NSCLC	0	None
2011-08-16	AVI BioPharma, MDA to initiate exon-51 Phase 2 trial in Duchenne muscular dystrophy	0	None
2011-08-16	Enrollment commences in Omthera's Epanova Phase III trial for hypertriglyceridemia	0	None
2011-08-16	Enrollment commences in RegeneRx RGN-259 Phase 2 trial for dry eye syndrome	0	None
2011-08-16	Toclizumab for juvenile rheumatoid arthritis	0	None
2011-08-15	Starpharma starts bacterial vaginosis prevention study of VivaGel	1	None
2011-08-15	Arrythmia drug may work in stroke prevention: Study	0	1
2011-08-11	Pacira second quarter total revenues increase to $3.6 million	0	None
2011-08-11	Aeras, OETC announce initiation of new TB vaccine Phase IIb trial in patients with HIV	0	None
2011-08-11	Gastroenterology journal publishes results of Lexicon LX1031 Phase 2 trial in IBS	0	None
2011-08-11	Positive results from two ADL5945 Phase 2 studies for opioid-induced constipation	0	None
2011-08-10	Israeli OCS approves $1.7M grant to support PROLOR's hGH-CTP program	0	None
2011-08-10	Glenmark commences Revamilast Phase IIb trial in chronic inflammatory disorders	0	None
2011-08-10	NCI, Pharmacyclics sign CRADA to develop PCI-32765 for blood cancers	0	5
2011-08-10	Current Medical Research & Opinion publishes new data on EVISTA for postmenopausal osteoporosis	0	None
2011-08-10	Trastuzumab drug increases risk of heart problems in elderly breast cancer patients	0	None
2011-08-10	Hydros-TA therapy provides next generation of osteoarthritis relief	0	None
2011-08-10	Enobia raises US$40M through private placement	0	None
2011-08-09	Positive data from Lexicon LX1032 Phase 2 study on carcinoid syndrome	0	None
2011-08-09	Criterium to manage Senesco's SNS01-T Phase Ib/2a multiple myeloma study	0	None
2011-08-09	Lexicon's second quarter revenues decrease 55% to $0.6 million	0	None
2011-08-09	Genentech, Array BioPharma sign oncology agreement for ChK-1 development program	0	None
2011-08-08	22nd Century initiates enrollment in Phase II-B clinical trial of X-22 for smoking cessation	0	None
2011-08-08	Unigene second quarter revenue decreases to $2.5 million	0	None
2011-08-08	Allergan receives positive opinion from Irish Medicines Board for BOTOX	0	None
2011-08-06	VIVUS announces additional data from phase 3 QNEXA studies on obesity	0	None
2011-08-05	Idera second quarter net loss increases to $6.3 million	0	None
2011-08-05	Alexza resubmits AZ-004 NDA for treatment of agitation in schizophrenia patients	0	None
2011-08-05	ESC to produce focused update on AF Guidelines following early termination of PALLAS Trial	0	None
2011-08-05	Takeda, Amylin discontinue pramlintide/metreleptin development program for obesity	0	None
2011-08-05	YM BioSciences reports preclinical results of CYT387 in multiple myeloma	0	None
2011-08-05	FDA grants Orphan Drug Designation to Kamada's AAT product for type 1 diabetes	0	None
2011-08-05	Positive results from Antares Pharma VIBEX MTX clinical study on RA	0	None
2011-08-05	OncoGenex second quarter revenue increases to $1.9 million	0	None
2011-08-04	Dyax initiates ecallantide Phase 2 trial for ACE inhibitor-induced angioedema	0	None
2011-08-04	Palatin confirms initiation of AZD2820 Phase 1 trial in obesity	0	None
2011-08-04	Positive results from hGH-CTP Phase II trial in growth hormone deficient adults	0	None
2011-08-04	NIH-funded study to assess biomarkers in the blood of TBI patients	0	None
2011-08-04	Pharming, Santarus reach SPA agreement with FDA for RHUCIN Phase III trial	0	None
2011-08-03	Acceleron, Celgene enter development collaboration for ACE-536 protein therapeutic to treat anemia	0	None
2011-08-03	Positive results from combination drug trial for late-stage ovarian cancer	0	None
2011-08-03	Risperidone does not appear to reduce military-related PTSD symptoms	0	None
2011-08-03	Memantine drug could boost cognitive function in people with Down syndrome	0	5
2011-08-03	GSK, NPS enter agreement to evaluate ronacaleret in new indications	0	None
2011-08-02	ARIAD reports $47.8 million net loss for second quarter 2011	0	None
2011-08-02	AstraZeneca recruits patients for KODIAC Phase III trial in opioid-induced constipation	1	None
2011-08-02	Positive results from Jennerex JX-594 proof-of-concept trial on metastatic melanoma	0	4
2011-08-02	Insmed receives FDA clinical hold order for ARIKACE phase 3 trials in CF and NTM	0	None
2011-08-02	Can-Fite commences CF101 phase 2/3 trial for treatment of Psoriasis	0	None
2011-08-01	Femta files IND with FDA for FM101 monoclonal antibody against RA	0	None
2011-08-01	Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer	0	None
2011-08-01	Cubist initiates CXA-201 Phase 3 trial in complicated urinary tract infections	0	None
2011-08-01	Stealth presents Bendavia at AHA's Cardiovascular Scientific Sessions	0	None
2011-07-30	UH Case Medical Center to commence Phase 1 clinical trial on TMC207	0	None
2011-07-30	UH Rainbow physicians to participate in two new clinical trials with AsthmaNet	0	None
2011-07-29	EGT transfers clinical grade lentiviral vector to MSKCC	0	None
2011-07-29	Positive data from BioMarin's MOR-100 Phase 1/2 extension study on Morquio syndrome	0	None
2011-07-29	Combination drug regimen safe and effective for renal transplant patients	0	None
2011-07-29	Polaris initiates ADI-PEG 20 Phase 3 trial in hepatocellular carcinoma	0	3
2011-07-29	Sorrento receives NIAID Phase I STTR grant to develop vaccines against C. difficile infection	0	None
2011-07-29	RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome	0	None
2011-07-28	Curis second quarter net loss increases to $4.9 million	0	None
2011-07-28	Inspiration presents OBI-1 pivotal study data on hemophilia at 23rd ISTH congress	0	None
2011-07-27	Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer	0	None
2011-07-27	Amphetamines can control ADHD symptoms in adults	0	4
2011-07-27	New preclinical data from Baxter's BAX 499 hemophilia study presented at ISTH	0	None
2011-07-27	Aeterna Zentaris completes AEZS-130 Phase 3 study for diagnosis of AGHD	0	None
2011-07-27	Ceridia completes CER006 Phase 1 Proof-of-Concept study in humans	0	None
2011-07-27	NSU, Immunotec collaborate to determine effects of Immunocal on children with ASD	0	3
2011-07-27	Positive data from two GSK's Promacta Phase III studies on hepatitis C-related thrombocytopenia	0	None
2011-07-26	Anavex presents data on neuroprotective evidence for lead compound for Alzheimer’s	0	None
2011-07-26	Selexis, CSL enter commercial license agreement for therapeutic antibody	0	None
2011-07-26	Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A	0	None
2011-07-26	Zinc lozenges might treat natural common cold infections	0	None
2011-07-26	Debiopharm, INC Research partner for clinical development programmes	0	None
2011-07-26	PharmaNet to assist BrainStorm in obtaining FDA approval for ALS human clinical trials	0	None
2011-07-26	Advaxis submits protocol revision for ADXS-HPV CIN Phase II study	0	None
2011-07-25	Adaptimmune announces opening of pilot clinical trial in synovial sarcoma	0	None
2011-07-25	Promising drug for Duchenne muscular dystrophy	1	5
2011-07-25	Genesis Biopharma partners with Lonza for Contego to treat metastatic melanoma	0	None
2011-07-25	Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy	0	None
2011-07-25	Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma	0	None
2011-07-25	Bionovo completes 13 weeks repeat dose animal toxicology studies for Menerba	0	None
2011-07-25	BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain	0	None
2011-07-25	Mayo Clinic trial to evaluate folate receptor alpha-targeted breast/ovarian cancer vaccine	0	None
2011-07-25	R-Tech Ueno announces protocol amendment of RK-023 Phase I trial for eyelash hypotrichosis	0	None
2011-07-22	22nd Century receives FDA approval for X-22 IND to conduct Phase II-B smoking cessation trial	0	None
2011-07-22	Enrollment begins in Repligen's RG1068 pilot study to improve detection, staging of pancreatic cancer	0	None
2011-07-22	UK regulators approve Europe's first clinical trial of plant-derived antibody for HIV	0	None
2011-07-22	Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer	0	None
2011-07-22	Inotek completes two stages of INO-8875 Phase 2b trial against glaucoma	0	None
2011-07-21	BioSante announces worldwide license of Melanoma Vaccine to Hussman Foundation	0	None
2011-07-21	Isis commences ISIS-PTP1BRx Phase 1 study in type 2 diabetes	0	None
2011-07-21	PAREXEL completes 100th Asian ethnobridging study	0	None
2011-07-21	Clinical Vaccine Immunology publishes NanoBio's NB-1008 influenza study results	0	None
2011-07-21	Children and adults with social withdrawal due to Fragile X may benefit from STX209	0	None
2011-07-21	Clinical study of anti-HIV antibody made from genetically modified tobacco plants	0	None
2011-07-21	Boosted REYATAZ shows durable viral suppression in women with HIV	0	None
2011-07-21	Bristol-Myers Squibb announces results of BMS-708163 Phase II study on Alzheimer's	0	None
2011-07-21	Promising results from phase I study of Genentech's GDC-0941 for advanced breast cancer	0	None
2011-07-20	Final SVR results from Pharmasset's PSI-7977 phase 2b study in HCV	0	None
2011-07-20	Three-drug regimen more effective for treating H. pylori infection	0	None
2011-07-20	NCCN experts recommend bevacizumab for treating metastatic breast cancer	0	None
2011-07-20	Chemotherapy combined with anti-cancer agent shows promise for treatment of aggressive breast cancers	0	None
2011-07-20	Investigational compound dapagliflozin receives negative recommendation from FDA Advisory Committee	0	None
2011-07-20	Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference	0	None
2011-07-20	Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma	0	None
2011-07-20	CEL-SCI expands licensing agreement with Teva for Multikine cancer drug	0	None
2011-07-19	Aeterna's AEZS-108 final Phase 2 results in endometrial cancer to be presented at ESGO 2011	0	None
2011-07-19	Convergence initiates CNV1014802 Phase II study in lumbosacral radiculopathy	0	None
2011-07-18	Upsher-Smith initiates USL261 ARTEMIS1 Phase III study for seizure clusters in epilepsy patients	0	None
2011-07-18	ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients	0	None
2011-07-18	Study: IL-2 monotherapy not effective as maintenance therapy for acute myeloid leukemia	0	None
2011-07-18	Positive results from levomilnacipran Phase III study for major depressive disorder	0	3
2011-07-18	SEEK HIV-v vaccine demonstrates 90% reduction in HIV viral load	0	5
2011-07-15	Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer	0	None
2011-07-15	CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint	0	None
2011-07-15	BioMarin commences BMN 673 Phase 1 trial in hematological malignancies	0	None
2011-07-14	Michael J. Fox Foundation awards Impax $400,000 grant for research of IPX066 for Parkinson’s disease	0	None
2011-07-14	Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza	0	None
2011-07-14	Eisai's DACOGEN sNDA for acute myeloid leukemia accepted by FDA for review	0	None
2011-07-14	PharmAthene demonstrates 36 month stability of rPA anthrax vaccine program candidate	0	None
2011-07-14	DARA's DB959 shows promise against type 2 diabetes	0	None
2011-07-14	Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT	0	None
2011-07-14	ASLAN, Array sign license agreement to develop ARRY-543 for solid tumors	0	None
2011-07-14	Fish oil consumption helps reduce inflammation, anxiety in healthy young people	0	None
2011-07-13	Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer	0	None
2011-07-13	UIC to begin STX209 clinical trial for treatment of autism spectrum disorders	0	None
2011-07-13	Blood cancer drug trial results questioned by FDA	0	1
2011-07-13	Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis	0	None
2011-07-13	Arena reports APD811 Phase 1 trial results against pulmonary arterial hypertension	0	None
2011-07-12	Enrollment complete in Advaxis ADXS-HPV Phase II CIN study	0	None
2011-07-11	Sinapis completes first clinical trial of lead drug for stroke and traumatic brain injury	0	None
2011-07-11	Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia	0	None
2011-07-11	FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression	0	None
2011-07-11	Sunshine Biopharma completes Adva-27a cytotoxicity study in Multidrug Resistant Breast Cancer cell line	0	None
2011-07-11	Combination therapy shows promise against HER2-positive metastatic breast cancer	0	None
2011-07-11	Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis	0	None
2011-07-11	Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes	0	None
2011-07-08	Top-line results from HyQ subcutaneous IG phase III study in patients with primary immunodeficiency	0	None
2011-07-08	Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea	0	None
2011-07-08	First dog enters ADXS-HER2 dose-ranging study in canine osteosarcoma	0	None
2011-07-08	Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck	0	None
2011-07-08	Collaborative research discovers broadly acting antibody against influenza viruses	0	None
2011-07-08	Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint	0	None
2011-07-08	Exenatide tQT clinical trial meets pre-specified primary endpoint	0	None
2011-07-08	Enrollment commences in InterMune's Esbriet Phase 3 study for IPF	0	None
2011-07-07	Study: Cancer patients with VTE do not benefit from IVCF and fondaparinux	0	None
2011-07-07	Amrubicin vs. topotecan Phase III trial against lung cancer presented at IASLC conference	0	None
2011-07-06	High-dose aspirin could help prevent cardiovascular disease in diabetic patients	0	None
2011-07-06	Older people, women and minorities enrolled less frequently in lung cancer drug trials	0	None
2011-07-06	Former smokers with lung cancer can benefit from celecoxib treatment	0	None
2011-07-05	Patients with high EGFR expression more likely to benefit from cetuximab plus chemotherapy	0	None
2011-07-05	Erlotinib phase III study results on lung cancer presented at IASLC conference	0	None
2011-07-01	FDA grants Advaxis pre-IND meeting for Advaxis-PSA immunotherapy for prostate cancer	0	None
2011-07-01	Tranexamic acid effective for patients with head injury	0	None
2011-07-01	Positive results from Nexavar Phase 2b trial on breast cancer presented at ASCO	0	None
2011-06-30	Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia	1	None
2011-06-30	Auxilium reports three year data from XIAFLEX CORDLESS study in Dupuytren's contracture	0	5
2011-06-30	PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint	0	None
2011-06-30	Positive final results from Medicago's H5N1 Avian Influenza VLP vaccine Phase II trial	0	None
2011-06-30	Novartis reports NVA237 Phase III trial results against COPD	0	None
2011-06-30	Conference examines lagging ethical guidelines in face of expanding clinical trials in developing countries	0	None
2011-06-30	Provectus presents additional data on PV-10 at two separate melanoma conferences	0	None
2011-06-29	Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing	0	None
2011-06-29	Zalicus commences Synavive SYNERGY Phase 2b clinical trial for rheumatoid arthritis	0	None
2011-06-29	Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET	0	None
2011-06-29	USPTO awards patent for key therapeutic ingredient in CNVN202 targeted molecular cancer therapy	0	None
2011-06-29	Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness	0	None
2011-06-29	Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet	0	None
2011-06-29	Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema	0	None
2011-06-29	Glybera gene therapy reduces pancreatitis risk in Lipoprotein Lipase Deficiency patients	0	None
2011-06-29	FDA clears Nuvo's IND for Lidocaine Spray formulation	0	None
2011-06-28	Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients	0	None
2011-06-28	FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma	0	None
2011-06-28	Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction	0	2
2011-06-28	BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia	0	None
2011-06-28	Pfizer to present PF-299 and crizotinib clinical trial data on ALK at WCLC 2011	0	None
2011-06-28	Ticagrelor drug with low-dose aspirin effective against acute coronary syndrome	0	None
2011-06-28	TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011	0	None
2011-06-28	Yale University: Gabapentin clinical study on epilepsy may have been a 'seeding trial'	0	None
2011-06-28	ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint	0	None
2011-06-28	Researchers, policy experts to examine issue of declining enrollment in clinical trials	0	None
2011-06-28	Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website	0	None
2011-06-28	Microbix renegotiates key terms of Hunan influenza vaccine joint venture	0	None
2011-06-28	Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure	0	None
2011-06-28	Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis	0	None
2011-06-27	New and effective diabetes drug seeking approval	0	5
2011-06-27	Nile completes dosing in Part B of cenderitide Phase I study for ADHF	0	None
2011-06-27	Cardium to purchase Transdel's business assets	0	None
2011-06-27	Positive top line data from Mimetogen MIM-D3 Phase II clinical trial for dry eye disease	0	None
2011-06-27	Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial	6	5
2011-06-27	Genentech, FORMA enter structurally innovative agreement for small molecule cancer program	0	None
2011-06-27	EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease	0	None
2011-06-27	FDA responds to EpiCept Ceplene SPA	0	None
2011-06-27	Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD	0	None
2011-06-27	Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer	0	None
2011-06-27	Biota reports preliminary data from CS-8958 Phase III trial against influenza	0	None
2011-06-27	Positive results from Stealth's Bendavia Phase I renal impairment study	0	None
2011-06-27	Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011	0	None
2011-06-27	New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011	0	4
2011-06-27	Boehringer Ingelheim, Lilly announce new data from linagliptin Phase III study on type 2 diabetes	0	5
2011-06-27	New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011	0	3.5
2011-06-27	Promising results from MGH's BCG Phase I trial on type I diabetes	1	None
2011-06-27	Diabetic patients can benefit from basal insulin analogs	0	None
2011-06-27	New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011	0	None
2011-06-24	PCIB reports main results of Amphinex Phase I/II study against multiple cancers	0	None
2011-06-24	InVasc commences INV-144 Phase IIa trial in chronic kidney disease	0	None
2011-06-24	Lithium can prevent aggregation of toxic proteins and cell loss linked with Parkinson's	0	None
2011-06-24	Nature News examines controversy surrounding Indian HPV vaccine trial	0	None
2011-06-24	Millennium reports ongoing MLN8237 Phase II study results on non-Hodgkin lymphoma	0	None
2011-06-24	Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011	0	None
2011-06-24	Oxytocin hormone holds promise for children with Prader-Willi syndrome	1	None
2011-06-24	Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS	0	1
2011-06-24	GeoVax opens third clinical trial site for testing HIV/AIDS vaccine	0	None
2011-06-24	Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer	0	None
2011-06-23	Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals	0	None
2011-06-23	FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency	0	None
2011-06-23	MAP to present LEVADEX data on migraine at 15th Congress of IHC	0	None
2011-06-23	Positive results from Neurelis NRL-1 Phase I pharmacokinetic study on acute repetitive seizures	0	None
2011-06-23	Monash researchers receive MMV Project of the Year award for new anti-malarial drug candidate	0	None
2011-06-23	Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes	0	None
2011-06-23	Telaprevir drug shows promise in curing hepatitis C infection	0	None
2011-06-22	Tobira commences cenicriviroc Phase IIb clinical trial for HIV infection	0	None
2011-06-22	Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder	0	None
2011-06-22	Naurex commences GLYX-13 Phase II trial in treatment-resistant depression	0	None
2011-06-22	Multiple abstracts on QNEXA long-term clinical study to be presented at ADA 2011	0	None
2011-06-22	Endotis commences EP217609 Phase IIa study in patients undergoing open-heart surgery	0	None
2011-06-22	Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD	0	None
2011-06-22	Positive topline results from Lipid Therapeutics LT-02 Phase IIb trial on ulcerative colitis	0	None
2011-06-22	Medivir initiates TMC649128 phase Ib trial in chronic hepatitis C	0	None
2011-06-22	Pycnogenol, CoQ10 combination boost heart function	0	4
2011-06-22	Results of African malaria vaccine trial expected later this year	0	None
2011-06-22	CEL-SCI announces results from Multikine Phase II trial on head and neck cancer	0	None
2011-06-22	Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint	0	1
2011-06-21	Seaside Therapeutics commences STX209 Phase 2b study in autism spectrum disorders	0	None
2011-06-21	DIA recognizes CAPRISA team for outstanding achievement in HIV prevention	0	None
2011-06-21	Positive results from LCP-Tacro Phase III trial in stable kidney transplant recipients	0	None
2011-06-21	Lorcaserin Phase 3 trial data on type 2 diabetes to be presented at ADA 2011	0	5
2011-06-21	Halozyme to present three data on Ultrafast Insulin programs at ADA 2011	0	None
2011-06-21	Lilly, Boehringer Ingelheim to present new data from diabetes portfolio at ADA scientific sessions	0	None
2011-06-21	New clinical trial to evaluate safety of tenofovir gel in breastfeeding, pregnant women	0	None
2011-06-21	Amylin to present data on investigational diabetes drug candidates at ADA annual meeting	0	None
2011-06-20	Initiation of ALD518/BMS-945429 Phase 2b clinical trial in RA triggers milestone payment to Alder	0	None
2011-06-20	Spectrum announces various clinical studies on ZEVALIN at ICML 2011	0	None
2011-06-20	Concert to advance CTP-499, C-21191 into Phase 2 trials for diabetic nephropathy and spasticity	0	5
2011-06-20	GTx commences Capesaris Phase IIb trial in advanced prostate cancer	0	None
2011-06-20	Alexion begins eculizumab clinical trial in Shiga-toxin producing E. coli hemolytic uremic syndrome	0	None
2011-06-20	Positive results from vismodegib Phase II study on advanced basal cell carcinoma	0	None
2011-06-20	Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011	0	None
2011-06-18	Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas	0	None
2011-06-17	Positive data from Ischemix CMX-2043 Phase 2a trial for peri-operative cardiac ischemia-reperfusion injury	0	None
2011-06-17	Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital	0	None
2011-06-17	Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL	0	None
2011-06-17	VIVUS Avanafil phase 3 trial on erectile dysfunction meets primary endpoints	0	None
2011-06-17	Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma	0	None
2011-06-17	REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference	0	None
2011-06-17	Pearl advances PT003 dual combination drug candidate into Phase 2 studies for treatment of COPD	0	None
2011-06-17	CTI announces positive results from Phase I-II pixantrone combination study against INHL	0	None
2011-06-17	Experimental vaccine shows promise for patients with newly diagnosed brain tumors	0	None
2011-06-17	Positive results from etanercept pilot study against dermatomyositis	0	None
2011-06-17	BioClinica releases new Trident IWR solution	0	None
2011-06-16	New Australian drug shows positive response in patients with multiple myeloma blood cancer	3	2.4
2011-06-16	Adaptimmune melanoma trial opening	0	None
2011-06-16	Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis	0	None
2011-06-16	Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia	0	None
2011-06-16	Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections	0	None
2011-06-16	Large trial of tenofovir gel for women set to begin in South Africa	0	None
2011-06-16	Positive results from BiondVax Multimeric-001 Phase IIa trial against influenza	0	None
2011-06-16	Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists	0	None
2011-06-16	Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011	0	None
2011-06-16	Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings	0	None
2011-06-16	Provectus PV-10 Phase 2 trial data on metastatic melanoma to be presented at two conferences	0	None
2011-06-16	Inviragen commences INV21 Phase 1 trial against Hand, Foot and Mouth Disease	0	None
2011-06-15	Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression	0	None
2011-06-15	Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID	0	None
2011-06-15	Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer	0	None
2011-06-15	immatics initiates IMA901 Phase III trial in renal cell carcinoma	0	None
2011-06-15	Meda presents new positive results from Dymista Phase-III trial on AR at EAACI 2011	0	None
2011-06-15	Sangart commences MP4OX Phase 2b study in acute traumatic injury	0	None
2011-06-15	Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen	0	None
2011-06-15	Positive results from Neurelis NRL-01 Phase 1 trial against epilepsy	0	None
2011-06-14	CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury	0	None
2011-06-14	The Lancet publishes final 3-year data from landmark HORIZONS-AMI clinical trial	0	None
2011-06-14	TWi Biotech enrolls over 50% of patients for AC-201 Phase IIb trial against Type II Diabetes	0	None
2011-06-14	New findings from Deplin clinical trial on major depressive disorder presented at NCDEU	1	5
2011-06-14	Orexo completes first OX27 pharmacokinetic trial against breakthrough pain in cancer	0	None
2011-06-14	GE Healthcare announces results of Optison heart ultrasound contrast agent presented at ASE	0	None
2011-06-14	FDA approves Cornell Dots for first-in-human clinical trial for treatment of cancer	0	None
2011-06-14	Cinryze data on hereditary angioedema presented at EAACI 2011	0	None
2011-06-14	Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML	0	None
2011-06-13	Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia	0	None
2011-06-13	Study reveals positive impact of Soliris on long-term outcomes in PNH patients	1	5
2011-06-13	CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary	0	None
2011-06-13	Trimeris, Synageva enter definitive merger agreement	0	None
2011-06-13	Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma	0	None
2011-06-13	Circassia announces ToleroMune vaccine phase II trial results against cat allergy	0	None
2011-06-13	Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials	0	None
2011-06-13	Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis	0	3
2011-06-13	Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA	0	None
2011-06-13	Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011	0	None
2011-06-10	Preliminary results from Edison's EPI-A0001 28-day phase 2A trial against Friedreich's ataxia	0	5
2011-06-10	Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function	0	4
2011-06-10	Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011	0	None
2011-06-10	FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma	0	None
2011-06-10	Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting	0	None
2011-06-09	Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease	0	None
2011-06-09	Promising results from VX-770 and VX-809 Phase 2 study for cystic fibrosis	0	5
2011-06-09	ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme	0	None
2011-06-09	Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis	0	None
2011-06-09	TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs	0	None
2011-06-09	Patient enrollment complete in cilengitide Phase III study against glioblastoma	0	3
2011-06-09	Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease	0	None
2011-06-09	FDA accepts Adamis IND for APC-100 to treat prostate cancer	0	None
2011-06-08	Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO	0	None
2011-06-08	Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection	0	None
2011-06-08	New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA	0	None
2011-06-08	Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C	0	None
2011-06-08	Millennium reports results from two VELCADE based combination studies against multiple myeloma	0	None
2011-06-08	Quest conducts first clinical Investigators Meeting for Oregovomab in Rome, provides corporate updates	0	None
2011-06-08	Vaccine candidate produces immune response to antigen in all strains of influenza A	0	None
2011-06-08	Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis	0	None
2011-06-08	Cabozantinib shows early promise in treatment of prostate cancer spread to the bone	0	None
2011-06-08	MSU professor to lead acetazolamide clinical trial on idiopathic intracranial hypertension	0	None
2011-06-08	MicroDose completes atropine inhaler Phase I study on nerve agent poisoning	0	None
2011-06-08	SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189	0	None
2011-06-08	Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne	0	None
2011-06-08	Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS	0	None
2011-06-07	Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011	0	None
2011-06-07	LLS announces four new Academic Concierge partnerships for cancer drug development	0	None
2011-06-07	Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences	1	None
2011-06-07	NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011	0	None
2011-06-07	ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011	0	None
2011-06-07	AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis	0	2
2011-06-07	Unique clinical trial addresses important questions about treating AIDS-related cancers	0	None
2011-06-07	Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011	0	4
2011-06-07	Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting	0	None
2011-06-07	FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold	0	None
2011-06-07	Independent investigators report Lymphoseek meets all endpoints in NEO3-09 Phase 3 study	0	None
2011-06-07	Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma	0	None
2011-06-07	Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer	0	None
2011-06-07	Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint	0	None
2011-06-07	SPI to commence enrollment in SPI-1005 clinical trial to prevent hearing loss induced by loud music	0	None
2011-06-07	Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011	0	None
2011-06-07	Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011	0	None
2011-06-07	VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011	0	None
2011-06-07	Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria	0	None
2011-06-07	Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC	0	None
2011-06-07	Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011	0	None
2011-06-07	Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011	0	None
2011-06-07	Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint	0	None
2011-06-07	Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011	0	4
2011-06-07	Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO	0	None
2011-06-06	Trifunctional antibody Catumaxomab triggers vaccination effect against cancer	0	None
2011-06-06	Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year	0	None
2011-06-06	Encouraging data from Cylene CX-4945 Phase I dose-escalation trial presented at ASCO 2011	0	None
2011-06-06	Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer	0	None
2011-06-06	Astellas to present positive AGS-1C4D4 phase II data in metastatic pancreatic cancer at ASCO 2011	0	None
2011-06-06	Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma	0	None
2011-06-06	Incyte seeks FDA marketing approval of ruxolitinib for myelofibrosis	0	None
2011-06-06	Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation	0	None
2011-06-06	Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011	0	None
2011-06-06	Amylin's metreleptin clinical study data on partial lipodystrophy presented at ENDO 2011	0	None
2011-06-06	Chiasma presents Octreolin pharmacology data from clinical studies at International Pituitary Congress	0	None
2011-06-06	GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC	0	None
2011-06-06	United Therapeutics completes oral treprostinil Phase 3 trial on pulmonary arterial hypertension	0	None
2011-06-06	NCIC CTG's exemestane clinical trial data on breast cancer presented at ASCO 2011	0	None
2011-06-06	Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC	0	None
2011-06-06	Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO	0	5
2011-06-06	Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO	0	None
2011-06-06	New targeted therapy may halt tumor growth in men with advanced prostate cancer	0	None
2011-06-06	Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO	0	5
2011-06-06	Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011	0	None
2011-06-06	New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO	0	1
2011-06-06	Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint	0	None
2011-06-06	ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011	0	None
2011-06-06	Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011	0	None
2011-06-06	Women with breast cancer do not benefit from flaxseed	0	None
2011-06-06	Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint	0	None
2011-06-06	Ipsen decides to assess development of Irosustat in combination with hormonal therapies	0	None
2011-06-06	Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer	0	None
2011-06-06	ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011	0	None
2011-06-06	Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011	0	None
2011-06-06	Exemestane reduces risk of breast cancer in high-risk, postmenopausal women	0	None
2011-06-06	Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma	0	None
2011-06-05	Ross River Fever vaccine trials begin	1	None
2011-06-04	Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer	0	None
2011-06-04	Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011	0	None
2011-06-04	Study links loss of PTEN gene with patient's response to melanoma therapy	0	None
2011-06-04	Impax announces results of IPX066 ADVANCE-PD and APEX-PD Phase III study against Parkinson's	0	None
2011-06-04	U of A researchers try to combat heart disease in cancer patients	0	None
2011-06-04	Bionovo's Menerba Phase 2 trial data to be presented at Annual World Congress on Menopause	0	5
2011-06-04	Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011	0	None
2011-06-04	Researcher to evaluate new approach for treatment of triple-negative breast cancer	0	None
2011-06-04	Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC	0	None
2011-06-04	Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma	0	None
2011-06-04	Nano-formulated indomethacin at lower dose effective in treating pain	0	5
2011-06-04	EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011	0	None
2011-06-04	Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011	0	None
2011-06-04	YM reports updated interim results from CYT387 Phase I/II study on myelofibrosis	0	None
2011-06-04	Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma	0	None
2011-06-04	Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer	0	None
2011-06-04	Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma	0	None
2011-06-03	Cancer vaccine shows improved response rate in patients	0	None
2011-06-03	ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011	0	None
2011-06-03	ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011	0	None
2011-06-03	APC8015F investigational vaccine improves survival of prostate cancer patients	0	None
2011-06-03	Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men	0	5
2011-06-03	Teva completes patient enrollment in COPAXONE Phase III trial for treatment of multiple sclerosis	0	None
2011-06-03	Angiotensin receptor blockers do not increase risk of cancer: FDA	0	None
2011-06-03	Positive interim results from iBio's H1N1 influenza subunit vaccine Phase 1 trial	0	None
2011-06-03	VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers	0	None
2011-06-02	Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome	0	None
2011-06-02	Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011	0	None
2011-06-02	Positive interim results from Fraunhofer USA CMB's HAC1 influenza vaccine Phase 1 trial	0	None
2011-06-02	AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011	0	None
2011-06-02	Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting	0	None
2011-06-02	Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab	0	None
2011-06-02	Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011	0	5
2011-06-02	Anadys receives U.S. patent for setrobuvir to treat chronic hepatitis C	0	None
2011-06-02	Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia	0	None
2011-06-02	Fero Industries completes Sucanon human clinical trials on Type-2 diabetes	0	None
2011-06-01	Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma	0	None
2011-06-01	Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011	0	5
2011-06-01	Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011	0	None
2011-06-01	Diamyd European Phase III study in diabetes does not meet primary endpoint	0	None
2011-06-01	CrystalGenomics begins enrollment in CG100649 Phase 2b osteoarthritis study	0	None
2011-06-01	Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease	0	None
2011-06-01	Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis	0	None
2011-05-31	Enrollment complete in BioSante's LibiGel Phase III cardiovascular and breast cancer safety study	0	None
2011-05-31	YM announces updates on nimotuzumab clinical development program	0	None
2011-05-30	Positive results from DavosLife Natural e3 phase I clinical trial in resectable pancreatic cancer	0	None
2011-05-30	New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting	0	None
2011-05-27	Interim analysis of AIM-HIGH study affirms positive impact of Niaspan on HDL and triglyceride lipid values	0	None
2011-05-27	Adalimumab plus methotrexate helps achieve higher levels of disease control in early RA	0	None
2011-05-27	NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol	1	4
2011-05-27	4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011	0	None
2011-05-27	ARCA plans to expand development program for Gencaro in atrial fibrillation	0	None
2011-05-27	Nuron secures option, license deal to develop NU400 for Relapse Remitting Multiple Sclerosis	0	None
2011-05-27	Positive results from CEL-SCI's LEAPS H1N1-activated dendritic cells trial in mice	0	5
2011-05-27	Tacrolimus prevents breast cancer growth in pre-clinical studies	0	None
2011-05-27	Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress	0	None
2011-05-27	Tigris Pharmaceuticals begins enrollment in AFP-464 Phase 2 trial in ER-positive breast cancer	0	None
2011-05-26	Gout drug success for Novartis	0	None
2011-05-26	Specific influenza immunization strategies for RA patients may be required for future flu pandemics	0	None
2011-05-26	iBioLaunch Platform successfully expresses hookworm-derived molecule for potential vaccine	0	None
2011-05-26	Pharmasset, Bristol-Myers Squibb initiate PSI-7977 plus BMS-790052 combination Phase 2a trial in HCV	0	None
2011-05-26	BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011	0	None
2011-05-26	ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011	0	None
2011-05-26	Mayoly-Spindler, ProteaBio complete MS1819 Phase I/IIA trial in malabsorption syndrome	0	None
2011-05-26	Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011	0	None
2011-05-26	NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial	0	None
2011-05-26	Lytix Biopharma completes two LTX-109 Phase I/IIa studies in MRSA, Gram+ skin infections	0	None
2011-05-26	Tofacitinib safe and effective for patients with rheumatoid arthritis	0	None
2011-05-26	Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout	0	None
2011-05-26	NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer	0	None
2011-05-25	PolyMedix presents new pre-clinical data on antimicrobial compounds at two scientific meetings	0	None
2011-05-25	Derma Sciences announces results of DSC127 Phase 2 trial in diabetic foot ulcers at 24-weeks	0	None
2011-05-25	Pathway receives FDA approval to commence PWT33597 Phase 1 study in advanced solid tumors	0	None
2011-05-25	Avanafil phase 3 trial in ED following radical prostatectomy meets primary endpoints	0	None
2011-05-25	New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology	0	None
2011-05-25	Oral and injected steroids appear to be equally effective for sudden hearing loss	0	None
2011-05-25	CRT, Cancer Research UK and Centella partner to launch clinical development of CEN-209	0	None
2011-05-25	Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011	0	None
2011-05-25	Conference reviews recent evidence that links aspirin use with reduced risk of several cancers	0	None
2011-05-25	New clinical research study to compare two medications for bipolar disorder	1	None
2011-05-25	Positive interim results from new bladder cancer therapy trial	0	None
2011-05-25	ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011	0	None
2011-05-24	Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis	0	None
2011-05-24	3M, Radius collaborate to develop BA058 for treatment of osteoporosis	0	None
2011-05-24	Azilsartan medoxomil-CLD phase 3 study results in systolic blood pressure presented at ASH 2011	0	5
2011-05-24	Altor receives NHLBI SBIR grant to complete ALT-836 second Phase 2 trial in ALI/ARDS	0	None
2011-05-24	VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011	0	None
2011-05-24	Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia	0	None
2011-05-24	Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma	0	None
2011-05-23	Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting	0	None
2011-05-23	Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011	0	None
2011-05-23	Micromet's blinatumomab data to be presented at two upcoming medical meetings	0	None
2011-05-23	Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting	0	None
2011-05-23	New RHUCIN study data in acute HAE attacks presented at 7th C1 Inhibitor Deficiency Workshop	0	None
2011-05-23	Phytoceuticals to present promising clinical data on 1 PRIMARY WOUND DRESSING at EWMA 2011	0	None
2011-05-23	New data from ProSavin Phase I/II trial in Parkinson's presented at ASGCT annual meeting	1	5
2011-05-23	Eplerenone reduces new onset atrial fibrillation and flutter in patients with class 2 heart failure	0	None
2011-05-21	Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination	0	None
2011-05-21	Phase 3 open-label study of RELISTOR presented at American Pain Society meeting	0	None
2011-05-21	Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting	0	None
2011-05-21	Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011	0	None
2011-05-20	Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer	0	None
2011-05-20	Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C	0	None
2011-05-20	RTOG reports on largest trial for newly diagnosed glioblastoma	0	None
2011-05-20	AMT presents long-term efficacy study of Glybera in treatment of lipoprotein lipase deficiency	0	5
2011-05-20	Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011	0	None
2011-05-20	VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT	0	None
2011-05-20	Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO	0	None
2011-05-20	Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma	0	None
2011-05-20	ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection	0	None
2011-05-20	CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia	0	5
2011-05-19	Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer	0	None
2011-05-19	Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence	0	None
2011-05-19	Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout	1	None
2011-05-19	PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies	0	None
2011-05-19	RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011	0	None
2011-05-19	Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy	0	None
2011-05-19	Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study	0	None
2011-05-19	Omeros advances OMS103HP and OMS302 into Phase 3 clinical programs	0	None
2011-05-19	AstraZeneca announces encouraging results from olaparib phase II study in serous ovarian cancer	0	None
2011-05-19	TissueGene commences enrollment in TG-C Phase II trial for severe knee osteoarthritis	0	None
2011-05-19	YM BioSciences announces updated interim results from CYT387 Phase I/II trial in myelofibrosis	0	None
2011-05-19	Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting	0	None
2011-05-19	Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints	0	None
2011-05-19	Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting	0	None
2011-05-19	Mpex, Synteract partner for cystic fibrosis fundraising event	0	None
2011-05-19	Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer	0	None
2011-05-18	Pharma Two B plans to initiate P2B001 Phase II study in Parkinson's disease	0	None
2011-05-18	New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting	0	None
2011-05-18	New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference	0	None
2011-05-18	JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia	0	5
2011-05-18	Bayer HealthCare to present results on investigational oncology compounds at ASCO annual meeting	0	None
2011-05-18	CITN selects Cytheris' CYT107 for initial clinical trials at network institutions	0	None
2011-05-18	Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer	0	None
2011-05-18	Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints	0	5
2011-05-18	Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting	0	None
2011-05-18	Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder	0	None
2011-05-18	CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada	0	None
2011-05-18	Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis	0	None
2011-05-17	Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma	0	None
2011-05-17	Thrombolytic therapy linked to poor survival in pulmonary embolism patients with normal blood pressure	0	None
2011-05-17	Sanofi hopes to launch dengue vaccine in 2014	0	4
2011-05-17	SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011	0	None
2011-05-17	Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study	0	None
2011-05-16	Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference	0	None
2011-05-16	Journal of Burn Care & Research publishes Caldolor clinical study data in hospitalized patients	0	3
2011-05-16	Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting	0	None
2011-05-16	Synexus completes CT327 phase II psoriasis trial for Creabilis	0	3
2011-05-16	New lenalidomide phase III study data presented at 13th International Myeloma Workshop	0	None
2011-05-16	Early HIV treatment can reduce transmission risk by 96%, preliminary study results show	0	None
2011-05-16	Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme	0	None
2011-05-16	VAYA Pharma's Vayarin now available in South, North Carolina and Texas for children with ADHD	1	3
2011-05-16	Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder	0	None
2011-05-16	The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis	0	None
2011-05-13	CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland	0	None
2011-05-13	ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer	0	None
2011-05-13	Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting	0	None
2011-05-13	Early antiretroviral treatment can halt HIV spread in couples	0	None
2011-05-12	Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment	0	None
2011-05-12	New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections	0	None
2011-05-12	CrystalGenomics receives draft CSR for CG400549 Phase I MAD study in Staph infections	0	None
2011-05-12	Atox Bio completes AB103 phase 1 study in severe bacterial infections and sepsis	0	None
2011-05-12	Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting	0	None
2011-05-12	Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting	0	None
2011-05-12	GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores	0	None
2011-05-11	Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment	0	None
2011-05-11	ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer	0	None
2011-05-11	Symphogen to present second-generation Sympress platform at ESACT conference	0	None
2011-05-11	TSA, Psyadon Pharmaceuticals partner for ecopipam clinical trial in Tourette Syndrome	0	None
2011-05-11	Impax Pharmaceuticals initiates IPX159 Phase I study in Restless Legs Syndrome	0	None
2011-05-11	GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011	0	None
2011-05-11	Two DIFICID Phase 3 trial data in C. difficile presented at DDW conference	0	None
2011-05-11	Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA	0	None
2011-05-11	Inovio first quarter total revenue increases to $3.1 million for 2011	0	None
2011-05-11	Two DIFICID Phase 3 study data in C. difficile presented at ECCMID conference	0	None
2011-05-11	New drug targets bile acid to provide relief from constipation	0	None
2011-05-11	New Crohn’s disease therapy on its way	1	None
2011-05-10	Dalbavancin surveillance antibiotic results for Gram-positive pathogens presented at ECCMID meeting	0	None
2011-05-10	Independent investigator begins pump trial of Biodel's two ultra-rapid human insulin formulations	0	None
2011-05-10	Tetraphase presents TP-434, TP-2758 antibiotics study data against pathogens at ECCMID	0	None
2011-05-10	biocrea and Pfizer jointly presented details on novel PDE10 inhibitors	0	None
2011-05-10	Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST	0	None
2011-05-10	Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients	0	None
2011-05-10	Pfizer presents SA3Ag staphylococcal vaccine Phase 1 trial data at ECCMID/ICC	0	None
2011-05-10	MGH, Duke University and Angion Biomedica partner to develop novel therapeutics for ischemic stroke	0	None
2011-05-10	OncoGenex first quarter revenue decreases to $1.2 million	0	None
2011-05-10	Kowa presents three K-115 study results against glaucoma at ARVO 2011	0	None
2011-05-10	Nexvax2- coeliac disease vaccine shows promising results in Phase I clinical trial	0	5
2011-05-10	Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting	0	None
2011-05-10	Abbott, Sucampo present lubiprostone phase 3 trial data in Japanese CIC at DDW 2011	0	None
2011-05-09	Uganda: First vaccination for GMZ2 malaria vaccine trial	0	None
2011-05-09	New GARDASIL data against Human Papillomavirus presented at EUROGIN conference	0	3
2011-05-09	GTx reports net loss of $2.6 million for first quarter 2011	0	None
2011-05-09	EMA agrees to Swedish Orphan Biovitrum, Biogen Idec's pediatric rFIXFc trial in hemophilia	0	None
2011-05-09	Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer	0	None
2011-05-09	Diamyd Medical announces European Phase III study results in type 1 diabetes	0	None
2011-05-07	Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting	0	None
2011-05-07	Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting	0	None
2011-05-06	ImmunoCellular reports updated ICT-107 Phase I trial data in glioblastoma multiforme	0	None
2011-05-06	Millennium presents three studies in relapsed multiple myeloma at IMW meeting	0	None
2011-05-06	Pacira to present EXPAREL data in postsurgical pain at two medical meetings	0	None
2011-05-06	Omeros' PDE7 program expands addiction franchise	0	None
2011-05-06	MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment	0	None
2011-05-06	Furiex Pharmaceuticals to present two JNJ-Q2 antibiotic abstracts at ECCMID/ ICC congress	0	None
2011-05-05	Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011	0	None
2011-05-05	Over 1000 patients enrolled in world's largest ever pancreatic cancer vaccine trial	0	None
2011-05-05	Clinical study: Celecoxib drug may treat breast cancer	0	None
2011-05-05	CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer	0	None
2011-05-05	Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease	0	None
2011-05-04	FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients	0	None
2011-05-04	PolyMedix Phase 1B/2 clinical study data presented at ATVB meeting	0	None
2011-05-04	SARcode reports encouraging data from SAR 1118 Phase 2 dry eye trial	0	None
2011-05-04	pSivida presents data of ILUVIEN Phase 3 trial in Diabetic Macular Edema at ARVO 2011	0	None
2011-05-04	Top-line results from Lymphoseek NEO3-09 Phase 3 study in breast cancer, melanoma	0	None
2011-05-03	Nile Therapeutics initiates cenderitide Phase I trial in heart failure	0	None
2011-05-03	Santarus' budesonide MMX Phase III data in ulcerative colitis to be presented at DDW 2011	0	None
2011-05-03	Affinium announces AFN-1252 Phase I study results in staphylococcal infections	0	None
2011-05-03	Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia	0	None
2011-05-03	Merck's Phase III study shows efficacy results of tafluprost to treat ocular hypertension	0	None
2011-05-03	Diabetes cell implant company approved for Argentina clinical trial	0	None
2011-05-02	Positive Ellex 2RT data demonstrates efficacy in treatment of early Age-Related Macular Degeneration	0	None
2011-04-30	Pearl's PT003 Phase 2b study results in COPD to be presented at ATS meeting	0	None
2011-04-30	CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada	0	None
2011-04-29	Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients	0	None
2011-04-29	MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals	0	None
2011-04-29	Top-line results from Pfizer's tofacitinib Phase 3 studies in RA	0	None
2011-04-28	CEL-SCI initiates Multikine Phase III trial in head and neck cancer	1	None
2011-04-28	FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer	0	None
2011-04-28	Curis reports first quarter net loss of $6.8 million	0	None
2011-04-28	Positive results from Otonomy's OTO-104 Phase 1b study in Meniere's disease	0	None
2011-04-28	Positive results from Shire's Vyvanse clinical trial in schizophrenia	0	3
2011-04-28	Novo Nordisk first quarter net profit increases 23% to DKK 4,073 million	0	None
2011-04-28	Molecular Partners completes MP0112 phase I/IIa trials in wet AMD, DME	0	None
2011-04-28	The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence	0	None
2011-04-28	Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women	0	None
2011-04-28	FDA Advisory Committee recommends approval of Merck's VICTRELIS for chronic HCV genotype 1 infection	0	None
2011-04-27	CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC	0	None
2011-04-27	Children, adolescents with liver disease may not benefit from vitamin E or metformin	0	None
2011-04-27	BioInvent, ThromboGenics initiate TB-402 Phase IIb trial for VTE prophylaxis	0	None
2011-04-27	Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV	0	2
2011-04-27	Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC	0	None
2011-04-27	IQ Therapeutics completes dosing in IQNLF Phase I trial for anthrax	0	None
2011-04-27	Tarix begins patient enrollment for TXA127 Phase 1 study in DCBT	0	None
2011-04-26	FDA supports new Hepatitis C drug from Vertex Pharmaceuticals	0	None
2011-04-26	Diabetes and prediabetes are on the rise: New medication in research trials	0	None
2011-04-26	Millennium submits two VELCADE sNDAs to FDA	0	None
2011-04-26	USPTO grants Cortex patent for CX1739 AMPAKINE molecule	0	None
2011-04-26	Pharmacyclics receives Servier's $7 million milestone payment for HDAC inhibitor	0	None
2011-04-26	Dactinomycin more effective for low-risk gestational tumor treatment	0	None
2011-04-26	HemaQuest initiates HQK-1001 Phase 2 study in sickle cell disease	0	None
2011-04-26	BMY to present belatacept Phase III new data at American Transplant Congress	0	None
2011-04-25	A.P. Pharma targets resubmission of APF530 NDA in 2012	0	None
2011-04-25	Curemark CM-182 demonstrates positive results for schizophrenia in transgenic chakragati model of psychosis	0	None
2011-04-25	XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis	0	None
2011-04-25	Individuals on SSRIs still exhibit depressive symptoms	0	None
2011-04-25	Pfizer comments on abstract concerning ORAL Sync tofacitinib Phase 3 study in RA	0	None
2011-04-25	Anacor's AN2728 and GSK '052 new data to be presented at upcoming meetings	0	None
2011-04-22	Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients	0	None
2011-04-22	Atrasentan provides no additional benefits in phase III clinical trial for advanced prostate cancer	0	None
2011-04-22	BioCryst's BCX4208 study results in gout to be presented at EULAR meeting	0	None
2011-04-22	Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting	0	None
2011-04-22	Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder	0	None
2011-04-22	Convergence initiates CNV2197944 Phase I study in chronic pain	0	None
2011-04-22	JASN publishes positive results from pirfenidone study in diabetic nephropathy	0	None
2011-04-21	Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine	0	None
2011-04-21	Merrimack initiates dosing in MM-111 combination Phase 1 study in advanced HER2 positive patients	0	None
2011-04-21	Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer	0	None
2011-04-21	Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications	0	None
2011-04-21	Stanford and SanBio initiate SB623 Phase 1/2a clinical trial for stroke disability	0	None
2011-04-21	New trial in UK to test whether statins could be used to treat pre-eclampsia	0	None
2011-04-21	Amgen, UCB report positive results from AMG 785/CDP7851 comparative Phase 2 study for postmenopausal osteoporosis	0	None
2011-04-20	Anavex: First-in-human dosing cmmenced in ANAVEX 2-73 clinical trial for Alzheimer’s	0	None
2011-04-20	Gilead, MicroDose enter collaboration for inhalable small molecule antiviral fusion inhibitor MDT-637	0	None
2011-04-20	Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011	0	None
2011-04-20	Aduro raises $19.25 million through Series B equity financing	0	None
2011-04-20	Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells	0	None
2011-04-20	Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer	0	None
2011-04-20	Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic	0	None
2011-04-20	Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections	0	None
2011-04-20	Advancell initiates ATH008 phase IIb study for hand-foot syndrome	0	None
2011-04-20	Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint	0	None
2011-04-20	Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal	0	None
2011-04-20	Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial	0	None
2011-04-19	African AIDS drug trial stopped prematurely	0	None
2011-04-19	NeuroVive, HCL initiate CicloMulsion Phase III trial in myocardial infarction	0	None
2011-04-19	Positive interim anemia response data from YM's CYT387 Phase I/II trial in myelofibrosis	0	None
2011-04-19	Circassia closes $98 million fundraising for lead allergy programmes	0	None
2011-04-19	Novartis NVA23 Phase III trial in COPD achieves primary end point	0	None
2011-04-19	Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL	0	None
2011-04-18	Japan Tobacco and Torii commence ferric citrate Phase 3 clinical program for hyperphosphatemia	0	None
2011-04-18	Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV	0	None
2011-04-18	Positive results from Nabriva's BC-3781 Phase II trial in ABSSSI	0	None
2011-04-18	Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides	0	None
2011-04-16	GRAVITAS study shows no benefit of double-dose compared with standard-dose clopidogrel	0	None
2011-04-16	Data of ImmunoCellular's lead dendritic cell cancer vaccine candidate for GBM presented at AAN meeting	0	None
2011-04-16	Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting	0	None
2011-04-16	New results from largest multicenter clinical trial for heart transplant patients be released at ISHLT 2011	0	None
2011-04-16	Opexa's Tovaxin Phase IIb study data in MS presented at AAN meeting	0	5
2011-04-15	Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis	0	None
2011-04-15	Cytonet initiates clinical trial using liver cell infusion to treat urea cycle disorders in children	0	None
2011-04-15	Investigational Alzheimer's compounds may treat neuropathies	0	None
2011-04-15	Halozyme announces Aspart-PH20 study results in type 1 diabetes	0	None
2011-04-15	Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS	0	None
2011-04-15	QRxPharma receives new U.S. Patent for MoxDuo IR in treatment of acute pain	0	None
2011-04-15	Perampanel drug can effectively treat seizures in patients with epilepsy	0	None
2011-04-12	Yissum announces successful Docetaxel pre-clinical data in cancer	0	None
2011-04-12	Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting	0	None
2011-04-12	Sirolimus may help treat lymphangioleiomyomatosis in women	0	None
2011-04-12	Positive results from ULCA's Phase 1 dendritic cell vaccine trial in glioblastoma	0	5
2011-04-12	Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN	0	None
2011-04-12	Novel drug holds potential against resistant chronic myeloid leukemia	0	None
2011-04-12	Laquinimod drug greatly reduces number of relapses in patients with MS	0	None
2011-04-12	Epilepsy medication USL255 associated with less fluctuation in plasma levels compared to topiramate IR	0	None
2011-04-11	NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma	0	None
2011-04-11	Vanda initiates Fanapt Phase I study in patients with schizophrenia	0	None
2011-04-11	Positive interim results from PROLOR's hGH-CTP Phase II trial in growth hormone deficiency	0	None
2011-04-11	Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS	0	None
2011-04-11	The Lancet publishes VIVUS 56-week QNEXA study results in obesity	0	None
2011-04-11	Blood journal to publish Soliris study results in Paroxysmal Nocturnal Haemoglobinuria	0	None
2011-04-11	Synexus' Chief Medical Officer to discuss vaccine trial challenges at Washington event	0	None
2011-04-11	New experimental drug can help treat peripheral neuropathy in cancer patients	0	5
2011-04-11	Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma	0	None
2011-04-11	Annals of Neurology publishes Diamyd Medical´s NP2 Enkephalin Phase I results in cancer pain	0	None
2011-04-11	Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection	0	None
2011-04-11	Gilenya can reduce risk of disability progression in patients with RRMS	0	None
2011-04-11	Investigational drug effective for patients with obesity	0	None
2011-04-11	New study finds no significant benefit of bosentan against IPF	0	None
2011-04-08	Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer	0	None
2011-04-08	FDA grants tentative approval for Hi-Tech Pharmacal's generic Combigan ANDA	0	None
2011-04-08	ViroXis' IND for EISO-derived product to treat HPV skin warts receives FDA approval	0	None
2011-04-08	HALT-C trial reveals high mortality rates among patients with HCV	0	5
2011-04-08	Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema	0	None
2011-04-08	Long-term delivery of CNTF slows loss of visual acuity caused by geographic atrophy	0	None
2011-04-08	Targacept's TC-5619 Phase 2 trial data in schizophrenia presented at ICOSR	0	None
2011-04-08	Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting	0	None
2011-04-07	Positive top-line results from Roche's T-DM1 Phase II trial in HER2-positive MBC	0	None
2011-04-07	MAP Pharma publishes LEVADEX Phase 3 FREEDOM-301 study data in 'Headache' journal	0	None
2011-04-07	Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting	0	None
2011-04-07	OncoGenex, Teva's custirsen preclinical data in CRPC presented at AACR meeting	0	None
2011-04-07	Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting	0	None
2011-04-07	Positive data from PROCHIEVE vaginal progesterone Phase III study published in peer-reviewed journal	0	None
2011-04-07	VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting	0	None
2011-04-06	Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers	0	None
2011-04-06	ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours	0	None
2011-04-06	Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011	0	None
2011-04-06	Celldex presents CDX-1127 preclinical data against cancer at AACR meeting	0	None
2011-04-06	Aeterna Zentaris presents AEZS-131 data against cancer at AACR meeting	0	None
2011-04-06	J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism	0	None
2011-04-06	Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting	0	None
2011-04-06	Avila's PI3Kα inhibitor preclinical study data presented at AACR meeting	0	None
2011-04-06	Pervasis' PVS-30200 study data in prostate cancer presented at AACR meeting	0	None
2011-04-06	Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia	0	None
2011-04-06	Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting	0	None
2011-04-05	ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers	0	None
2011-04-05	Incyte earns $15M milestone payment from Novartis for INCB28060 Phase I dose-escalation cancer trial	0	None
2011-04-05	R&D Directions names Novavax VLP influenza vaccine as one of top '100 great investigational drugs in development'	0	4.5
2011-04-05	RE-LY trial results suggest Pradaxa capsule reduces risk of stroke in AF patients	0	None
2011-04-05	Aeterna Zentaris presents two posters on perifosine at AACR meeting	0	None
2011-04-05	OncoGenex presents OGX-427 preclinical data in prostrate cancer at AACR meeting	0	None
2011-04-05	Synta presents ganetespib and elesclomol study data in cancer at AACR meeting	0	None
2011-04-05	Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting	0	None
2011-04-05	Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting	0	None
2011-04-05	Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia	0	None
2011-04-05	Current Alzheimer Research publishes ExonHit's EHT 0202 Phase IIa results	0	None
2011-04-05	Cardioxyl's CXL-1020 preclinical data against heart failure presented at ACC meeting	0	None
2011-04-04	Daiichi Sankyo acquires Plexxikon	0	None
2011-04-04	Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients	0	None
2011-04-04	Aspirin usage associated with decrease in pancreatic cancer risk	0	None
2011-04-04	ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting	0	None
2011-04-04	Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting	0	None
2011-04-04	ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting	0	None
2011-04-04	Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting	0	None
2011-04-04	Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury	0	None
2011-04-04	Human immune system can help predict recurrence, overall breast cancer survival	0	None
2011-04-04	BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV	0	5
2011-04-04	BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV	0	None
2011-04-04	Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL	0	None
2011-04-04	Positive results from GDC-0973, GDC-0941 combination therapy Phase I trial against cancer	0	None
2011-04-04	New data: Quadruple therapy can effectively treat patients with HCV	0	None
2011-04-04	New data finds PegIFN-lambda shows RVR in HCV patients with improved safety, tolerability	0	None
2011-04-04	Positive results from GDC-0449 Phase II data against basal cell nevus syndrome	0	None
2011-04-02	Pfizer to present new investigational compounds data against cancer at AACR meeting	0	None
2011-04-02	Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting	0	None
2011-04-02	MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting	0	None
2011-04-02	Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting	0	None
2011-04-02	Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335	0	None
2011-04-02	Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress	0	None
2011-04-01	Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL	0	None
2011-04-01	Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting	0	None
2011-04-01	APEX-PD Phase III clinical study data to be presented at American Academy of Neurology Conference	0	None
2011-04-01	Obeticholic Acid safe and effective against Primary Biliary Cirrhosis	1	3.3
2011-04-01	Omeros announces outcome from OMS103HP Phase 3 study in patients undergoing ACL surgery	0	None
2011-04-01	Novartis, Intercell to initiate Pseudomonas vaccine trial in ventilated ICU patients	0	None
2011-04-01	Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting	0	1.5
2011-04-01	CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury	0	None
2011-04-01	VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting	0	None
2011-04-01	Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas	0	None
2011-04-01	Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting	0	5
2011-04-01	Vertex announces final results from Phase 3 REALIZE study against HCV	0	None
2011-04-01	Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting	0	None
2011-04-01	Syndax to present entinostat data against cancer at AACR meeting	0	None
2011-04-01	Positive outcome from Orexo's OX51 initial pharmacokinetic trial to treat acute intensive pain	0	None
2011-04-01	Positive results from Intercept OCA Phase II trial in patients with PBC	0	None
2011-04-01	Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer	0	None
2011-03-31	Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus	0	None
2011-03-31	Anavex screening volunteers for phase I, first-in-human clinical study in Alzheimer’s	0	None
2011-03-31	FDA grants Nile Fast Track designation for cenderitide post-acute development program	0	None
2011-03-31	Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder	0	None
2011-03-31	Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C	0	None
2011-03-31	Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV	0	None
2011-03-31	NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV	0	None
2011-03-31	Molecular Templates ETB preclinical data against cancer to be presented at AACR meeting	0	None
2011-03-31	Positive outcomes from imatinib trial in both older and younger patients with CML	0	None
2011-03-31	Glasgow Professor discusses about new approach for CML treatment at UK conference	0	None
2011-03-31	CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel	0	None
2011-03-31	Boceprevir drug can help cure hard-to-treat hepatitis C	0	None
2011-03-31	Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC	0	None
2011-03-31	Three-drug cocktail more effective against hepatitis C virus	0	None
2011-03-31	Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting	0	None
2011-03-30	MonoSol Rx receives positive FDA feedback on 505(b)(2) pathway for Montelukast Sodium OSF	0	None
2011-03-30	Amgen announces top-line results from motesanib Phase 3 trial against NSCLC	0	None
2011-03-30	BioSante completes patient enrollment in LibiGel Phase III trial against HSDD	0	None
2011-03-30	Pharmasset commences PSI-7977 Phase 2b study against HCV	0	None
2011-03-30	Columbia Labs' PROCHIEVE Phase III trial results to be published in online medical journal	0	None
2011-03-30	SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting	0	None
2011-03-30	Positive preliminary results from Presidio's PPI-461 Phase 1b trial against HCV	0	None
2011-03-30	Positive results from Vertex VX-770 Phase 3 trial against CF	0	None
2011-03-30	Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis	0	None
2011-03-30	Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes	0	None
2011-03-29	New lung cancer drug starts human trials	0	None
2011-03-29	Concert initiates CTP-499 Phase 1 study in patients with diabetic nephropathy	0	None
2011-03-29	Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit	0	None
2011-03-29	Keryx KRX-0401 trial data against colorectal cancer, multiple myeloma to be presented at AACR	0	None
2011-03-29	Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma	0	None
2011-03-29	International Phase II trial to study LY2181308 efficacy in patients with lung cancer	0	None
2011-03-29	CytRx to present bafetinib preclinical study results at AACR Annual Meeting	0	None
2011-03-29	Nordion presents TheraSphere Phase II trial results against liver metastases at SIR meeting	0	None
2011-03-28	Dementia & Alzheimer’s drug trial with sleep hormone melatonin	0	None
2011-03-28	PHOENIX phase III trial of PHP for distributive shock to continue after positive midpoint recommendation from DMB	0	None
2011-03-28	ActiveSite's ASP-440 plasma kallikrein inhibitor effective in reducing diabetes-induced blood-retinal barrier breakdown	0	None
2011-03-28	Bionovo initiates enrollment in Menerba Phase 1 clinical trial for menopausal hot flushes	0	None
2011-03-28	Dosing commences in Phase I clinical study of GenSpera's G-202 at Cancer Therapy & Research Center	0	None
2011-03-28	Pathway Medical initiates enrollment in JETSTREAM G3 Calcium Study in peripheral artery disease	0	None
2011-03-28	Phase 2a study of DARA BioSciences KRN5500 in treatment of cancer pain reaches primary end-point	0	None
2011-03-28	Cancer drug Gleevec may hold promise against scleroderma: Study	0	5
2011-03-28	AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting	0	None
2011-03-28	NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS	0	None
2011-03-28	Genentech's Lucentis Phase III trials in DME meets primary endpoints	0	None
2011-03-25	XTL announces MinoGuard acquisition	0	None
2011-03-25	Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer	0	None
2011-03-25	Purdue demonstrates efficacy of Butrans transdermal delivery system for chronic pain in opioid-naive patients	0	None
2011-03-25	Isotechnika fourth quarter consolidated net loss increases to $2.42 million	0	None
2011-03-25	Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology	0	None
2011-03-25	Study examines regional analgesia effect on long-term outcomes in soldiers with combat injuries	0	None
2011-03-25	SARcode's SAR 1118 Phase 2 data against dry eye to be presented at ARVO meeting	0	None
2011-03-25	Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke	0	None
2011-03-25	Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD	0	None
2011-03-25	Positive top-line results from POZEN's PA32540 Phase 1 study against cardiovascular disease	0	None
2011-03-25	Oncolytics completes patient enrollment in REOLYSIN Phase 2 trial against head, neck cancers	0	None
2011-03-25	Clinical trial to determine whether Crestor can prevent new colon tumors after surgery	0	None
2011-03-25	Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis	0	None
2011-03-24	Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting	0	None
2011-03-24	Study demonstrates superiority of Spiriva over salmeterol in reducing risk of exacerbations in COPD	0	None
2011-03-24	Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting	0	None
2011-03-24	Rapid treatment within an hour of injury dramatically cuts bleeding deaths in injured patients	0	None
2011-03-24	Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder	0	None
2011-03-24	Gilead's elvitegravir Phase III trial against HIV-1 meets primary objective	0	None
2011-03-24	Oramed reports successful completion of ORMD-0801 oral insulin toxicity study	0	None
2011-03-24	KaloBios commences KB004 Phase 1 trial in patients with leukemia	0	None
2011-03-23	Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery	0	None
2011-03-23	MnSOD oral drug can protect against lung cancer radiation therapy	0	None
2011-03-23	Clinical trial to evaluate efficacy of PRP for osteoarthritis pain treatment	0	None
2011-03-23	Jefferson begins patient recruitment for new clinical trail to prevent colon cancer	0	None
2011-03-23	ViroPharma presents Cinryze data against HAE at AAAAI Annual Meeting	0	None
2011-03-23	Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA	0	None
2011-03-23	Use of fibrates for high lipid levels increases despite uncertain improvement in clinical outcomes	0	None
2011-03-23	FDA approves Harvest's BMAC System IDE trial to treat non-reconstructable Critical Limb Ischemia	0	None
2011-03-23	Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients	0	None
2011-03-23	Cellerant commences CLT-008 Phase I/II trial in patients with leukemia	0	None
2011-03-23	Enrollment complete in Aradigm's inhaled ciprofloxacin Phase 2b study in non-cystic fibrosis bronchiectasis	0	5
2011-03-23	Astellas announces positive results from mirabegron phase III trials against OAB	0	5
2011-03-23	Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI	0	None
2011-03-22	Five year course of tamoxifen can offer long-term benefit for women with breast cancer	0	None
2011-03-22	Positive results from Meda's Dymista Phase III trial in patients with SAR	0	None
2011-03-22	Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting	0	None
2011-03-22	CSL Behring presents Hizentra study data against PI at AAAAI meeting	0	None
2011-03-22	Ventirx VTX-1463 positive clinical data against allergic rhinitis presented at AAAAI meeting	0	None
2011-03-22	Polypill may serve as viable option for developing countries to treat CVD risk prevention	0	None
2011-03-22	ACE, ARB combination therapy may increase risk of kidney failure, death	0	None
2011-03-22	BMY's ipilimumab Phase III study against metastatic melanoma meets primary endpoint	0	None
2011-03-21	Second US trial in HIV/AIDS lymphoma patients using Benitec’s ddRNAi technology	0	None
2011-03-21	Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer	0	None
2011-03-21	Curemark reaches targeted enrollment in CM-AT Phase III clinical trials for autism	0	None
2011-03-21	NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis	0	None
2011-03-21	FDA clears Insmed IND for ARIKACE Phase 3 clinical trial in nontuberculous mycobacteria lung infections	0	None
2011-03-21	Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain	0	None
2011-03-21	NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza	0	None
2011-03-21	United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension	0	None
2011-03-21	Advanced Cell Technology reduces 2010 debt to less than $1 million	0	None
2011-03-21	Medicago launches clinical development of seasonal flu vaccine	0	None
2011-03-21	Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema	0	None
2011-03-21	XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD	0	None
2011-03-21	Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma	0	None
2011-03-21	CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma	0	None
2011-03-21	Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint	0	None
2011-03-19	BioMarin announces preliminary results from ADAPT in patients suffering from PKU	0	None
2011-03-19	The Lancet publishes Oceana's Solesta injectable gel study results against fecal incontinence	0	None
2011-03-19	Quark Pharmaceuticals receives results from Phase 2 trial of PF-04523655 in patients with DME	0	None
2011-03-19	Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma	0	None
2011-03-18	Science journal publishes CYTK preclinical cardiac myosin activation research results	0	None
2011-03-18	KYTHERA presents additional data from third ATX-101 Phase II clinical study in submental fat reduction	0	None
2011-03-18	Individualized dentritic cell vaccine may increase survival time in patients with glioblastoma	0	None
2011-03-18	FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease	0	None
2011-03-17	CytRx commences INNO-206 Phase 1b trial in advanced solid tumors	0	None
2011-03-17	PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting	0	None
2011-03-17	New lozenge clinical trial for dry mouth treatment	1	None
2011-03-17	HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers	0	None
2011-03-17	Digna Biotech and Biotecnol to begin CT-I Phase I trial in healthy volunteers	0	None
2011-03-17	Specific type of selenium supplement may help prevent cancer	0	None
2011-03-17	The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD	0	4
2011-03-16	Fibrocell Science submits azficel-T final study report to FDA	0	None
2011-03-16	RegeneRx RGN-352 Phase 2 trial in acute myocardial infarction placed on clinical hold	0	None
2011-03-16	Cortex enters agreement with Biovail to regain AMPAKINE assets and rights	0	None
2011-03-16	NIH awards TriLink $100,000 Phase I SBIR Grant to develop Hot Start approach for Ligase Chain Reaction	0	None
2011-03-16	Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome	0	None
2011-03-16	Plexxikon selects Clinipace to manage 4 clinical trials for RA treatment	0	None
2011-03-16	AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation	0	None
2011-03-16	Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis	0	None
2011-03-16	iTherX commences ITX-5061 Phase 1b study in patients with HCV	0	None
2011-03-15	Apeiron in antitumor substances deal with Cleveland Clinic	0	None
2011-03-15	Anavex to commence phase I clinical trial in Alzheimer’s disease	0	None
2011-03-15	Additional research needed for oral PrEP to treat HIV	0	None
2011-03-15	CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial	0	None
2011-03-15	Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint	0	5
2011-03-15	Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy	0	None
2011-03-15	Cerenis commences CER-001 Phase 2 CHI-SQUARE study in patients with ACS	0	None
2011-03-15	Positive top-line results from IPX066 Phase III study in patients with PD	0	None
2011-03-14	Repligen reports positive results from RG1068 Phase 3 study to improve MRI of the pancreas	0	None
2011-03-14	Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder	0	None
2011-03-14	Positive results from azide drug-loaded Emulsiphan preclinical toxicity study	0	None
2011-03-14	Biodel selects BIOD-105, BIOD-107 recombinant human insulin formulations for clinical testing, development	0	None
2011-03-14	KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism	0	None
2011-03-14	Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder	0	None
2011-03-14	Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides	0	None
2011-03-14	Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis	0	None
2011-03-14	ChronTech initiates ChronVac-C DNA vaccine Phase IIb study against HCV	0	None
2011-03-14	BioInvent commences BI-204 phase II study in patients with acute coronary syndrome	0	None
2011-03-14	Combination therapy may overcome Herceptin-resistant breast cancer	0	None
2011-03-12	Alzheimer's vaccine - First evidence for efficacy	0	5
2011-03-11	Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint	0	None
2011-03-11	Supernus SPN-812 Phase IIa U.S. clinical trial in ADHD meets primary endpoints	0	None
2011-03-11	Inhibitex fourth quarter net loss increases to $7.0 million	0	None
2011-03-11	Synta fourth-quarter total collaboration revenue decreases to $3.0 million	0	None
2011-03-11	Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC	0	None
2011-03-11	Genentech announces positive outcomes from Lucentis Phase III trial against DME	0	None
2011-03-11	Sildenafil helps improve exercise performance in children with congenital heart disease	0	None
2011-03-10	Positive preliminary results from Sinovac EV71 vaccine phase I trial in adults	0	None
2011-03-10	Positive results from exenatide phase 2 study in patients with type 2 diabetes	0	None
2011-03-10	Biothera announces acquisition of AS1402 anti-cancer monoclonal antibody from Antisoma	0	None
2011-03-10	Idera reports $6.0 million net loss for fourth quarter 2010	0	None
2011-03-10	Positive results from Creabilis CT327 Phase IIa study in patients with psoriasis vulgaris	0	None
2011-03-10	Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases	0	None
2011-03-10	CTI announces final pixantrone clinical trial design for treatment of DLBCL	0	None
2011-03-10	FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids	0	None
2011-03-10	Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia	0	None
2011-03-10	TARIS commences LiRIS Phase 1B clinical study in interstitial cystitis	0	None
2011-03-09	NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease	0	None
2011-03-09	Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease	0	5
2011-03-09	ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL	0	None
2011-03-09	Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting	0	None
2011-03-09	Vermillion's CA125 positive preliminary data against ovarian tumors presented at WCSGO	0	5
2011-03-09	Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study	0	None
2011-03-09	Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting	0	3
2011-03-09	FDA approves Ipsen's application for Extended Dosing Interval of Somatuline Depot for acromegaly	0	None
2011-03-09	FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease	0	None
2011-03-09	Unique gene therapy to combat Parkinson's disease	0	None
2011-03-09	Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD	0	None
2011-03-08	Treatment with sildenafil significantly reduces RP in patients with scleroderma	0	None
2011-03-08	Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma	0	None
2011-03-08	Conflicts of interest overlooked in drug trial reviews: Study	0	None
2011-03-08	Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA	0	None
2011-03-08	Compugen reports positive results from CGEN-25068 in animal model to treat certain disease conditions	0	None
2011-03-08	BMY to present new Phase II data on investigational hepatitis C compounds at ILC	0	None
2011-03-08	Fumaric acid salts may protect against Multiple Sclerosis	0	None
2011-03-08	New clinical trial to assess antiretroviral treatment in HIV-infected individuals based on CD4 counts	0	1
2011-03-08	Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression	0	None
2011-03-07	Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer	0	None
2011-03-07	USPTO grants patent to Symphogen's Sym004 to treat solid tumors	0	None
2011-03-07	Duchenne Parent Project awards grant to AMT for DMD gene therapy	0	None
2011-03-07	TapImmune provides clinical development clarification based on March 1 Press Release	0	None
2011-03-05	Researchers use qMRI to confirm effect of CS treatment in patients with OA	0	None
2011-03-05	Combination therapy may reduce albuminuria in patients with type 2 diabetes: Study	0	None
2011-03-05	Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints	0	None
2011-03-04	Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI	0	None
2011-03-04	Nevirapine reduces HIV transmission risk from mother to breastfeeding infants by 75%	0	None
2011-03-04	BioSante vaccine increases median survival of resected pancreatic cancer patients	0	None
2011-03-04	Ekomed to collaborate with Immune Network and Immunitor for further research of Immunoxel/Dzherelo	0	None
2011-03-04	Talecris granted EU orphan drug designation for Plasmin (human) to treat acute peripheral arterial occlusion	0	None
2011-03-04	Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL	0	None
2011-03-04	Palatin receives FDA clearance to begin PL-3994 Phase 2A trial for asthma treatment	0	None
2011-03-03	Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA	0	None
2011-03-03	Clinical trials in Australia take too long– need uniform standards: Report	0	None
2011-03-03	Glenmark Generics granted final FDA approval for generic Xyzal ANDA	0	None
2011-03-03	Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA	0	None
2011-03-03	Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer	0	None
2011-03-03	Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV	0	None
2011-03-03	Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal	0	None
2011-03-03	Depomed completes patient enrollment in Breeze 3 Serada Phase 3 trial to treat menopausal hot flashes	0	None
2011-03-03	Lixte receives $244,479.25 U.S. government grant for QTDP program	0	None
2011-03-03	Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV	0	None
2011-03-03	Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine	0	None
2011-03-03	EpiCept: Positive outcome from Ceplene Phase III trial in patients with AML	0	None
2011-03-03	Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack	0	None
2011-03-02	FDA accepts Handa's generic DEXILANT ANDA for review	0	None
2011-03-02	Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI	0	None
2011-03-02	Mylan confirms lawsuit relating to Estradiol Transdermal System ANDA	0	None
2011-03-02	Allergan initiates AGN-214868 Phase II trials in post herpetic neuralgia and overactive bladder	0	None
2011-03-02	Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder	0	None
2011-03-02	Scientists at retrovirus conference present findings on microbicide gel, Truvada, male circumcision, ART care by nurses	0	None
2011-03-02	Geron's hESC derived GRNCM1 halts remodeling process and preserves cardiac function in acute heart damage	0	None
2011-03-02	NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer	0	None
2011-03-02	OneWorld Health receives FDA clearance for iOWH032 phase 1 trials to treat secretory diarrhea	0	None
2011-03-01	Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis	0	None
2011-03-01	Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL	0	None
2011-03-01	Tenofovir gel more effective than oral tablet for HIV treatment: Study	0	None
2011-03-01	Positive preliminary data from SB-728-902 Phase 1 trial against HIV/AIDS presented at 18th CROI	0	None
2011-02-28	Omni Bio to expand Type 1 diabetes Phase I/II trial from 15 to 50 patients	0	None
2011-02-28	TCD announces first patient treated in its TCD-717 Phase I trial	0	None
2011-02-28	ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer	0	None
2011-02-28	Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study	0	None
2011-02-28	Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty	0	None
2011-02-28	Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL	0	None
2011-02-28	Positive results from Trius torezolid Phase 1 lung study	0	None
2011-02-28	Immunitor to present latest results from imm01 trial in tuberculosis patients at African conference	0	None
2011-02-28	MEPs, OETC visit new TB vaccine trial site to express support for candidate development	0	5
2011-02-28	Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder	0	None
2011-02-28	First patient treated in KUR-023 pilot clinical trial to assess safety and efficacy of product candidate	0	None
2011-02-28	Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference	0	None
2011-02-27	Phase III trial results: Erlotinib has comparable efficacy to chemotherapy with better tolerability against lung cancer	0	None
2011-02-27	Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer	0	None
2011-02-25	Less-toxic combination of immune-based drug and chemotherapy drug produce long-term remissions in CLL	0	None
2011-02-25	Neoprobe's Lymphoseek Phase 2 study data published in Annals of Surgical Oncology	0	None
2011-02-25	Preclinical data of Zalicus sodium channel compound published in journal PAIN	0	None
2011-02-25	Medwell commits $2,000,000 investment in Mimetogen	0	None
2011-02-25	U.S.-Chile collaborate to study new long-acting local anesthetic derived from algae	0	None
2011-02-25	Targets against MRSA in microgravity	0	None
2011-02-25	Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease	0	None
2011-02-25	Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection	0	None
2011-02-25	Radioactive tracing agent can identify tumor-draining sentinel nodes in breast cancer, melanoma patients	0	None
2011-02-25	The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases	0	3
2011-02-25	Enobia completes patient enrollment in ENB-0040 Phase II study for HPP	0	None
2011-02-25	Lux initiates pivotal voclosporin Phase 3 trial in non-infectious uveitis	0	None
2011-02-25	Zoledronic acid demonstrates anti-angiogenic effects in metastatic lung cancer	0	None
2011-02-25	Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells	0	None
2011-02-25	BioCryst receives HHS contract to complete peramivir Phase 3 study in patients with influenza	0	None
2011-02-24	PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections	0	None
2011-02-24	BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD	0	None
2011-02-24	Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP	0	None
2011-02-24	Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment	0	None
2011-02-24	Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF	0	None
2011-02-24	First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant	0	None
2011-02-23	Oncolytics completes patient enrollment in REOLYSIN trial to treat metastatic colorectal cancer	0	None
2011-02-23	PCI Biotech completes patient inclusion in PC-A11 phase I/II study to treat cancer	0	None
2011-02-23	Trevena commences TRV120027 Phase 2a trial in patients with acute heart failure	0	None
2011-02-23	Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic	0	None
2011-02-23	Aeterna to present two novel anticancer compounds at Bio Partnering North America conference	0	None
2011-02-23	Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery	0	None
2011-02-23	ISCTM 7th annual meeting to discuss drug development based on amyloid hypothesis of Alzheimer's disease	0	None
2011-02-23	Scientists receive HHS grant to investigate DSC127 in treatment of skin injuries linked with radiation exposure	0	None
2011-02-23	Survey: 67% of pharma and biotech companies outsource more than half of all clinical trials	0	None
2011-02-23	Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology	0	None
2011-02-23	American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer	0	None
2011-02-23	Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD	0	4
2011-02-22	Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD	0	None
2011-02-22	TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes	0	None
2011-02-22	Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer	0	None
2011-02-22	KemPharm commences KP201 Phase 1 trial for pain	0	None
2011-02-22	Pieris: New interim PRS-050 Phase I data against cancer to be presented at Tri-Conference in California	0	None
2011-02-22	Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions	0	None
2011-02-22	Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema	0	None
2011-02-22	Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV	0	None
2011-02-21	Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia	0	None
2011-02-21	Synexus creates specialist vaccines team to help pharma and biotech companies	0	None
2011-02-20	Bangladesh cholera vaccine trial	0	None
2011-02-19	Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium	0	None
2011-02-19	Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease	0	None
2011-02-19	Phase I/II safety, efficacy data for Bellicum's BPX-101 presented at 2011 Genitourinary Cancers Symposium	0	None
2011-02-19	EMA grants Prima BioMed Scientific Advice for CVac ovarian cancer vaccine Phase III trial	0	5
2011-02-19	FDA grants CSL Behring marketing approval for Corifact in treatment of congenital FXIII deficiency	0	None
2011-02-19	Novavax announces final safety, immunogenicity results from H1N1 VLP vaccine at WHO meeting	0	4.5
2011-02-18	Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV	0	None
2011-02-18	Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial	0	None
2011-02-18	BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain	0	None
2011-02-18	Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences	0	None
2011-02-18	Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol	0	None
2011-02-18	FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera	0	None
2011-02-18	Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment	0	None
2011-02-17	Cytochroma initiates CTAP101 repeat-dose safety, efficacy study in vitamin D insufficiency, SHPT and CKD	0	None
2011-02-17	Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer	0	None
2011-02-17	Clinical trial finds atorvastatin may inhibit HIV progression, help in infection's management	0	None
2011-02-17	FDA, Threshold enter agreement on SPA for TH-302 Phase 3 trial in patients with soft tissue sarcoma	0	None
2011-02-17	Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease	0	None
2011-02-17	Oncolytics begins enrollment in 2-Arm carboplatin Phase II randomized study for pancreatic cancer	0	None
2011-02-16	Endo Pharmaceuticals, Bioniche announce first patient enrollment in Urocidin second Phase III trial	0	None
2011-02-16	Endologix announces initial PEVAR Trial presentation at 2011 iCON annual meeting	0	None
2011-02-16	Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL	0	2
2011-02-15	The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza	0	None
2011-02-15	Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis	0	None
2011-02-15	Almac's Director plans to speak on adaptive trial designs at CTS Europe conference	0	None
2011-02-15	Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters	0	None
2011-02-15	Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint	0	None
2011-02-14	Kamada reports positive interim results from Alpha-Antitrypsin Phase 2-3 trial to treat Alpha-1 deficiency	0	None
2011-02-14	FDA waives NDA filing fee for Antares' Anturol NDA	0	None
2011-02-14	FDA grants BrainStorm's NurOwn orphan drug designation for treatment of ALS	0	None
2011-02-14	Neoprobe achieves accrual goal in Lymphoseek Phase 3 study in breast cancer/melanoma	0	5
2011-02-14	Tarsa completes oral calcitonin Phase III trial for treatment of postmenopausal osteoporosis	0	None
2011-02-14	OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer	0	None
2011-02-14	Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea	0	2
2011-02-14	Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol	0	None
2011-02-14	SynthRx to become wholly-owned subsidiary of ADVENTRX	0	None
2011-02-14	Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis	0	None
2011-02-14	Phase III RISE study of Lucentis for DME meets primary endpoint	0	None
2011-02-14	Last patient in EU Diamyd Phase III clinical study completes 15-month visit for type 1 diabetes	0	None
2011-02-14	JTH publishes positive TB-402 Phase II trial results for VTE treatment after orthopaedic surgery	0	None
2011-02-13	Positive safety data from BioSante's ongoing LibiGel Phase III study in women with HSDD	0	None
2011-02-11	FDA grants Inhibitex Fast Track Designation for INX-189 in treatment of chronic hepatitis C viral infection	0	None
2011-02-11	Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF	0	None
2011-02-10	Medivir initiates phase 1a clinical trial of TMC649128 for chronic HCV infection	0	None
2011-02-10	Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer	0	None
2011-02-10	Gilead resubmits NDA for single-tablet regimen of Truvada/TMC278	0	None
2011-02-10	Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain	0	None
2011-02-10	EMA grants QLT positive opinions for Orphan Drug Designation of QLT091001 to treat inherited blindness	0	5
2011-02-10	Vical 2010 net loss increases to $30.4 million	0	None
2011-02-10	Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors	0	None
2011-02-10	Diamyd's NP2 Enkephalin Phase II study in cancer pain posted on ClinicalTrials.gov	0	None
2011-02-10	Hormone 17-Hydroxyprogesterone does not reduce rate of preterm delivery in twin pregnancies: Study	0	None
2011-02-10	Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial	0	None
2011-02-09	Everolimus phase III study shows improved progression-free survival in patients with pNET	0	None
2011-02-09	Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes	0	None
2011-02-09	PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI	0	None
2011-02-09	GeoVax opens second HIV clinical trial site at Alabama Vaccine Research Clinic	0	None
2011-02-09	CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders	0	None
2011-02-09	A.P. Pharma provides update on response to APF530 Complete Response Letter	0	None
2011-02-09	R-Tech commences RK-023 Phase I study for treatment of eyelash hypotrichosis	0	None
2011-02-09	Gentium completes Defibrotide clinical studies, plans to file for regulatory approval	0	None
2011-02-09	Medicago granted FDA clearance for clinical development of seasonal flu vaccine	0	None
2011-02-09	Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients	0	None
2011-02-08	CytRx's bafetinib helps reduce skeletal complications in cancer patients	0	None
2011-02-08	Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI	0	None
2011-02-08	Scientists develop low cost, nanometer-sized drug to treat chronic wounds	0	None
2011-02-08	Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint	0	5
2011-02-08	Cleveland Clinic, JumpStart Ventures invest $500,000 in SironRX Therapeutics	0	None
2011-02-08	Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010	0	None
2011-02-07	PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors	0	None
2011-02-07	Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer	0	None
2011-02-07	AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder	0	None
2011-02-07	The Lancet journal publishes BENLYSTA BLISS-52 study against SLE	0	None
2011-02-07	Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN	0	None
2011-02-05	Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology	0	None
2011-02-05	Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA	0	None
2011-02-04	Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis	0	None
2011-02-04	Positive results from Photocure's Allumera RevitAll study to improve skin's appearance	0	None
2011-02-04	EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal	0	None
2011-02-04	Positive results from KYTHERA's ATX-101 Phase IIb study for reduction of submental fat	0	None
2011-02-04	FDA sets new PDUFA date for AstraZeneca's ticagrelor	0	None
2011-02-04	CVBT seeks FDA 'fast track' designation for CVBT-141B to treat ischemic diabetic wounds	0	None
2011-02-04	MicroCHIPS commences first hPTH clinical study in women with osteoporosis	0	None
2011-02-04	Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME	0	None
2011-02-04	Positive top-line results from ILUVIEN Phase 3 trial in patients with DME	0	5
2011-02-03	Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease	0	None
2011-02-03	Positive results from Derma Sciences' Phase 2 trial with DSC127 in patients with diabetic foot ulcers	0	None
2011-02-03	New England Journal publishes fidaxomicin Phase 3 trial results against CDI	0	5
2011-02-03	Inspiration presents IB1001 PK data for treatment of hemophilia B	0	None
2011-02-03	First therapeutic vaccine designed from dendritic cells of patient achieves significant response	0	None
2011-02-03	Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV	0	None
2011-02-03	Fidaxomicin demonstrates 45% reduction in recurrences vs. existing treatment for C. difficile infection	0	None
2011-02-03	Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI	0	None
2011-02-03	Inspiration presents IB1001 PK data at European haemophilia congress	0	None
2011-02-03	Merck announces publication of GARDASIL pivotal Phase III study data in NEJM	0	1
2011-02-03	Isotechnika closes licensing deal with ILJIN Life Science to advance development of voclosporin	0	None
2011-02-03	FDA lifts clinical hold on Icagen's IND for ICA-105665 epilepsy drug candidate	0	None
2011-02-03	ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM	0	None
2011-02-03	Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC	0	None
2011-02-03	Positive results from Factor IX-CTP comparative study in hemophilic mice	0	None
2011-02-02	EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer	0	None
2011-02-02	Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders	0	None
2011-02-02	DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011	0	None
2011-02-02	Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer	0	None
2011-02-02	FDA to inspect Lannett's manufacturing facility for review of Morphine Sulfate NDA	0	None
2011-02-02	Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes	0	None
2011-02-02	FDA issues Complete Response Letter for approval of Eisai's rabeprazole sodium extended-release capsules	0	None
2011-02-02	Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis	0	5
2011-02-01	BioMarin commences GALNS Phase 3 trial in patients with Morquio A Syndrome	0	3
2011-02-01	Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial	0	None
2011-02-01	Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine	0	None
2011-02-01	Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA	0	None
2011-02-01	Discovery Labs provides expanded update on efforts to gain FDA marketing authorization for Surfaxin in RDS	0	None
2011-02-01	AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma	0	5
2011-02-01	Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment	0	None
2011-02-01	Highly favorable final results from ERGOFLEX initial clinical study for joint pain relief	0	None
2011-02-01	Positive results from NRM8499 phase I clinical study in patients with Alzheimer's disease	0	None
2011-02-01	FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma	0	None
2011-01-31	VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers	0	None
2011-01-31	Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis	0	None
2011-01-31	GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS	0	None
2011-01-31	Scientists to commence new DNA vaccine trial for use in patients with leukemia	0	None
2011-01-31	Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial	0	None
2011-01-29	Phase III study shows tapentadol ER relieves chronic pain associated with DPN	0	None
2011-01-28	Naprosyn used in Iroko's Phase I pharmacokinetic study of naproxen	0	None
2011-01-28	Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint	0	None
2011-01-28	Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents	0	1
2011-01-28	Cetero Research completes 20,000th early-phase clinical study	0	None
2011-01-28	Arena reduces workforce by 25% and provides update on lorcaserin	0	None
2011-01-28	Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting	0	None
2011-01-28	Receptos begins RPC1063 Phase 1 clinical study in patients with multiple sclerosis	0	5
2011-01-28	Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal	0	5
2011-01-27	Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer	0	None
2011-01-27	Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis	0	None
2011-01-27	Phase III study affirms safety and efficacy of Cumberland's Caldolor for post-operative pain	0	None
2011-01-27	Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion	0	None
2011-01-26	ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis	1	None
2011-01-26	Anadys begins dosing in ANA598 Phase IIb study for hepatitis C	0	None
2011-01-25	FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine	0	None
2011-01-25	Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia	0	None
2011-01-25	Northwest Biotherapeutics resumes enrollment in DCVax Phase II brain cancer clinical trial	0	None
2011-01-25	Diamyd Medical reports first quarter group total net sales of MSEK 144.5	0	None
2011-01-25	PharmaEngine presents PEP02 phase II studies in gastric and pancreatic cancers at ASCO 2011	0	None
2011-01-25	Eisai to seek marketing authorization for perampanel in the U.S. and EU	0	None
2011-01-25	Eisai's eritoran ACCESS study in severe sepsis does not meet primary endpoint	0	None
2011-01-25	Diamyd Medical to report European Phase III trial results for type 1 diabetes	0	None
2011-01-25	Promising results from TheraTears Nutrition pilot trial in dry eye patients	1	None
2011-01-24	Unrealistic optimism appears common in early cancer trials	0	None
2011-01-24	Furiex's MuDelta for diarrhea-predominant irritable bowel syndrome receives FDA Fast Track designation	0	None
2011-01-24	ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011	0	5
2011-01-24	Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer	0	None
2011-01-24	Alexza's AZ-004 Phase 3 study in agitated patients with schizophrenia published in British Journal of Psychiatry	0	None
2011-01-24	Senesco files SNS01-T IND for treatment of multiple myeloma	0	None
2011-01-24	Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer	0	None
2011-01-24	Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis	0	4
2011-01-24	Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis	0	None
2011-01-24	R-Tech Ueno announces completion of RK-023 Phase 2a study for androgenetic alopecia	0	None
2011-01-24	SuppreMol completes successful pre-IND meeting with U.S. FDA	0	5
2011-01-23	FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer	0	None
2011-01-21	Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer	0	5
2011-01-21	Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011	0	None
2011-01-21	Sunshine and Binghamton University enter research agreement for cancer compound	0	None
2011-01-21	MedImmune announces MEDI-573 preclinical results against many solid tumors	0	None
2011-01-21	Pervasis to present PVS-10200 interim data from Phase 1/2 PAD clinical study at IC3D	0	None
2011-01-21	Teva invests $3.95M in Rexahn for development of anti-cancer compound RX-3117	0	4
2011-01-21	MGH Bipolar CHOICE trial to evaluate effectiveness of new medications compared to lithium	0	None
2011-01-21	Positive results from nimotuzumab Phase II study for gastric cancer	0	5
2011-01-21	ACT Biotech releases telatinib Phase 2 trial data for metastatic stomach cancer	0	None
2011-01-20	Preliminary top-line results from levomilnacipran Phase III study for MDD	0	None
2011-01-20	FDA accepts Vertex's telaprevir NDA for six-month Priority Review	0	4.8
2011-01-20	Cognition Therapeutics closes $2.5 million Series A1 financing	0	None
2011-01-20	FDA grants Soligenix Orphan Drug Designation to RiVax for prevention of ricin intoxication	0	None
2011-01-20	Chelsea reports top-line data from Phase III NORTHERA extension study in NOH	0	None
2011-01-20	ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma	0	None
2011-01-20	Merck provides additional information about DSMB recommendations for vorapaxar TRA-2P study	0	None
2011-01-20	FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology	0	None
2011-01-20	Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma	0	None
2011-01-20	Koronis' KP-1461 drug causes extra mutations to occur in HIV genome in HIV-infected patients	0	None
2011-01-20	4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer	0	None
2011-01-20	Apricus Bio's MycoVa demonstrates 'non-inferiority' for treatment of onychomycosis compared to Loceryl	0	None
2011-01-20	FDA establishes PDUFA date for ADVENTRX's Exelbine NDA review	0	None
2011-01-20	GSK and Prosensa commence GSK2402968 Phase III study in DMD	0	4
2011-01-20	Biomarin commences BMN 701 Phase 1/2 trial for treatment of Pompe disease	0	None
2011-01-20	Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia	0	None
2011-01-19	Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia	0	None
2011-01-19	Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development	0	None
2011-01-19	Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas	0	None
2011-01-19	New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux	0	None
2011-01-19	RG7204 Phase III study shows significant survival benefit in patients with metastatic melanoma	0	None
2011-01-19	Arrowhead increases ownership in Calando's outstanding equity to 79%	0	None
2011-01-19	Positive results from PLX4032 Phase 3 Trial in patients with metastatic melanoma	0	1
2011-01-19	UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients	0	None
2011-01-18	NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer	0	None
2011-01-18	Alexza completes FDA review for AZ-004 NDA	0	None
2011-01-18	RTS,S offers 46 percent protection against malaria for at least 15 months after vaccination, Study finds	0	None
2011-01-18	Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV	0	None
2011-01-17	Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain	0	None
2011-01-14	Advaxis receives DSMB approval to complete dosing in first leg of ADXS11-001 cervical dysplasia clinical trial	0	4.3
2011-01-14	Merck announces changes in vorapaxar clinical studies	0	None
2011-01-13	Adjunctive lacosamide reduces seizures and improves responder rates	0	None
2011-01-13	BioCryst reports positive results from peramivir Phase 3 study in influenza	0	None
2011-01-13	BP-lowering medications provide long-term benefit of reducing death risk from cardiovascular disease	0	None
2011-01-13	FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis	0	3
2011-01-13	MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma	0	None
2011-01-13	Researchers launch estrogen therapy trial to study depression, cardiovascular illness in women	0	None
2011-01-13	TKM-PLK1 drug may offer hope for patients with advanced solid tumor cancers	0	None
2011-01-13	Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer	0	None
2011-01-12	AstraZeneca, CANCER RESEARCH UK enter strategic alliance to conduct experimental cancer drug trials	0	None
2011-01-12	GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease	0	5
2011-01-12	Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC	0	None
2011-01-12	Scientists find way to prevent early stage pancreatic cancer in research models	0	5
2011-01-12	Epigenetic therapy holds promise for cancer management	0	None
2011-01-12	UH, Case Western University commence clinical trial for bipolar disorder	0	1
2011-01-11	Rib-X raises $20M to support development of broad spectrum antibiotics pipeline	0	None
2011-01-11	FemmePharma completes FP 1097 Phase II clinical trial in women with OAB	0	None
2011-01-11	SciClone initiates phase 2b study of SCV-O7 for oral mucositis	0	None
2011-01-11	ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis	0	None
2011-01-11	Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML	0	None
2011-01-11	Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma	0	1
2011-01-11	Study supports use of telomerase inhibitors for treatment of childhood cancers	0	5
2011-01-11	Bioheart announces primary focus on completing clinical evaluation of cell therapies for heart failure	0	None
2011-01-11	TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders	0	None
2011-01-11	DAPT shows positive outcomes following treatment with OrbusNeich's Genous Stent	0	None
2011-01-11	Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV	0	None
2011-01-11	Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval	0	None
2011-01-11	NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome	0	None
2011-01-11	LibiGel may be the first FDA approved product to treat HSDD in menopausal women	0	5
2011-01-10	Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia	0	5
2011-01-10	Celator, Cephalon extend cancer research agreement	0	None
2011-01-10	Advanced Targeting Systems awarded $3 million NCI grant to advance SP-SAP clinical program	0	None
2011-01-10	Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea	0	None
2011-01-10	Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation	0	None
2011-01-10	Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy	0	None
2011-01-10	Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer	0	None
2011-01-10	Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study	0	None
2011-01-10	FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer	0	None
2011-01-10	KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat	0	3
2011-01-10	Positive preclinical results from Inovio's novel DNA vaccine targeting HIV Clade C virus	0	None
2011-01-10	FDA, EMA accept boceprevir for expedited review	0	None
2011-01-10	Positive PK study results from ECLIPSE trial against cardiovascular disease	0	None
2011-01-10	Positive results form INX-189 Phase 1b trial against hepatitis C virus	0	5
2011-01-09	AFQ056 drug improves symptoms in Fragile X patients: Study	0	None
2011-01-07	MedImmune announces in-licensing agreement with Amgen for IL-1 pathway targeting novel monoclonal antibody	0	None
2011-01-07	Synergy's plecanatide Phase II/III trial to begin in second quarter 2011	0	None
2011-01-07	Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen	0	None
2011-01-07	Chimerix initiates enrollment in CMX001 clinical study for life-threatening conditions caused by dsDNA viruses	0	5
2011-01-07	Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction	0	None
2011-01-07	BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer	0	None
2011-01-07	Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs	0	None
2011-01-07	Plexxikon, Genentech enter PLX4032 co-promotion agreement	0	None
2011-01-07	ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly	0	None
2011-01-07	Positive results from LifeCycle Pharma's LCP-Tacro comparative trial in de novo liver transplant patients	0	None
2011-01-07	Athersys completes patient enrollment in MultiStem Phase I study for leukemia	0	None
2011-01-07	Nippon Kayaku begins apaziquone Phase 1 bladder cancer study in Japan	0	None
2011-01-07	Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases	0	None
2011-01-07	Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol	0	None
2011-01-07	CeNeRx commences TriRima Phase II trial for treatment resistant depression	0	None
2011-01-06	Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis	0	None
2011-01-06	Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy	0	None
2011-01-06	MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer	0	None
2011-01-06	Choosing between EGFR therapeutic options in metastatic colorectal cancer	0	None
2011-01-06	Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211	0	2
2011-01-06	Profectus BioSciences commences GENEVAX IL-12 phase 1 study for HIV	0	None
2011-01-06	Sanofi-aventis announces publication of positive BSI-201 phase II results for breast cancer	0	None
2011-01-06	Positive topline results from ZGN-433 Phase 1b study in obesity patients	0	4.5
2011-01-06	Insite Vision announces completion of patient enrollment in ISV-303 Phase 1/2 trial for post surgical ocular pain, inflammation	0	None
2011-01-06	DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes	0	None
2011-01-05	Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis	0	None
2011-01-05	SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML	0	1
2011-01-05	Alnylam presents ALN-VSP Phase I trial results for liver cancer	0	None
2011-01-05	Vaccinex receives FDA clearance to initiate VX15/2503 Phase 1 clinical trial in advanced solid tumors	0	None
2011-01-05	Spectrum submits FUSILEV sNDA for treatment of colorectal cancer	0	None
2011-01-05	FDA lifts clinical hold on Hemispherx's Alferon LDO Phase II study for influenza prevention	0	None
2011-01-05	Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease	0	None
2011-01-04	Anadys begins ANA598 Phase IIb study for hepatitis C	0	None
2011-01-04	FDA approves ImmunoCellular Therapeutics IND amendment for ICT-107 Phase II clinical trial	0	None
2011-01-04	Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer	0	None
2011-01-03	Repros receives IRB approval for Androxal Phase IIb study in secondary hypogonadism	0	None
2011-01-03	FDA authorizes Juventas' JVS-100 Phase II clinical trial for critical limb ischemia	0	None
2011-01-03	Top-line results of TIGER-2 Phase 3 clinical trial for CF treatment	0	None